<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030004337A1-20030102-C00001.CDX SYSTEM "US20030004337A1-20030102-C00001.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00001.MOL SYSTEM "US20030004337A1-20030102-C00001.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00001.TIF SYSTEM "US20030004337A1-20030102-C00001.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00002.CDX SYSTEM "US20030004337A1-20030102-C00002.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00002.MOL SYSTEM "US20030004337A1-20030102-C00002.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00002.TIF SYSTEM "US20030004337A1-20030102-C00002.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00003.CDX SYSTEM "US20030004337A1-20030102-C00003.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00003.MOL SYSTEM "US20030004337A1-20030102-C00003.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00003.TIF SYSTEM "US20030004337A1-20030102-C00003.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00004.CDX SYSTEM "US20030004337A1-20030102-C00004.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00004.MOL SYSTEM "US20030004337A1-20030102-C00004.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00004.TIF SYSTEM "US20030004337A1-20030102-C00004.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00005.CDX SYSTEM "US20030004337A1-20030102-C00005.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00005.MOL SYSTEM "US20030004337A1-20030102-C00005.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00005.TIF SYSTEM "US20030004337A1-20030102-C00005.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00006.CDX SYSTEM "US20030004337A1-20030102-C00006.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00006.MOL SYSTEM "US20030004337A1-20030102-C00006.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00006.TIF SYSTEM "US20030004337A1-20030102-C00006.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00007.CDX SYSTEM "US20030004337A1-20030102-C00007.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00007.MOL SYSTEM "US20030004337A1-20030102-C00007.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00007.TIF SYSTEM "US20030004337A1-20030102-C00007.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00008.CDX SYSTEM "US20030004337A1-20030102-C00008.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00008.MOL SYSTEM "US20030004337A1-20030102-C00008.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00008.TIF SYSTEM "US20030004337A1-20030102-C00008.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00009.CDX SYSTEM "US20030004337A1-20030102-C00009.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00009.MOL SYSTEM "US20030004337A1-20030102-C00009.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00009.TIF SYSTEM "US20030004337A1-20030102-C00009.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00010.CDX SYSTEM "US20030004337A1-20030102-C00010.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00010.MOL SYSTEM "US20030004337A1-20030102-C00010.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00010.TIF SYSTEM "US20030004337A1-20030102-C00010.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00011.CDX SYSTEM "US20030004337A1-20030102-C00011.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00011.MOL SYSTEM "US20030004337A1-20030102-C00011.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00011.TIF SYSTEM "US20030004337A1-20030102-C00011.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00012.CDX SYSTEM "US20030004337A1-20030102-C00012.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00012.MOL SYSTEM "US20030004337A1-20030102-C00012.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00012.TIF SYSTEM "US20030004337A1-20030102-C00012.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00013.CDX SYSTEM "US20030004337A1-20030102-C00013.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00013.MOL SYSTEM "US20030004337A1-20030102-C00013.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00013.TIF SYSTEM "US20030004337A1-20030102-C00013.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00014.CDX SYSTEM "US20030004337A1-20030102-C00014.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00014.MOL SYSTEM "US20030004337A1-20030102-C00014.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00014.TIF SYSTEM "US20030004337A1-20030102-C00014.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00015.CDX SYSTEM "US20030004337A1-20030102-C00015.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00015.MOL SYSTEM "US20030004337A1-20030102-C00015.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00015.TIF SYSTEM "US20030004337A1-20030102-C00015.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00016.CDX SYSTEM "US20030004337A1-20030102-C00016.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00016.MOL SYSTEM "US20030004337A1-20030102-C00016.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00016.TIF SYSTEM "US20030004337A1-20030102-C00016.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00017.CDX SYSTEM "US20030004337A1-20030102-C00017.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00017.MOL SYSTEM "US20030004337A1-20030102-C00017.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00017.TIF SYSTEM "US20030004337A1-20030102-C00017.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00018.CDX SYSTEM "US20030004337A1-20030102-C00018.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00018.MOL SYSTEM "US20030004337A1-20030102-C00018.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00018.TIF SYSTEM "US20030004337A1-20030102-C00018.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00019.CDX SYSTEM "US20030004337A1-20030102-C00019.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00019.MOL SYSTEM "US20030004337A1-20030102-C00019.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00019.TIF SYSTEM "US20030004337A1-20030102-C00019.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00020.CDX SYSTEM "US20030004337A1-20030102-C00020.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00020.MOL SYSTEM "US20030004337A1-20030102-C00020.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00020.TIF SYSTEM "US20030004337A1-20030102-C00020.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00021.CDX SYSTEM "US20030004337A1-20030102-C00021.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00021.MOL SYSTEM "US20030004337A1-20030102-C00021.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00021.TIF SYSTEM "US20030004337A1-20030102-C00021.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00022.CDX SYSTEM "US20030004337A1-20030102-C00022.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00022.MOL SYSTEM "US20030004337A1-20030102-C00022.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00022.TIF SYSTEM "US20030004337A1-20030102-C00022.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00023.CDX SYSTEM "US20030004337A1-20030102-C00023.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00023.MOL SYSTEM "US20030004337A1-20030102-C00023.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00023.TIF SYSTEM "US20030004337A1-20030102-C00023.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00024.CDX SYSTEM "US20030004337A1-20030102-C00024.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00024.MOL SYSTEM "US20030004337A1-20030102-C00024.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00024.TIF SYSTEM "US20030004337A1-20030102-C00024.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00025.CDX SYSTEM "US20030004337A1-20030102-C00025.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00025.MOL SYSTEM "US20030004337A1-20030102-C00025.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00025.TIF SYSTEM "US20030004337A1-20030102-C00025.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00026.CDX SYSTEM "US20030004337A1-20030102-C00026.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00026.MOL SYSTEM "US20030004337A1-20030102-C00026.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00026.TIF SYSTEM "US20030004337A1-20030102-C00026.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00027.CDX SYSTEM "US20030004337A1-20030102-C00027.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00027.MOL SYSTEM "US20030004337A1-20030102-C00027.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00027.TIF SYSTEM "US20030004337A1-20030102-C00027.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00028.CDX SYSTEM "US20030004337A1-20030102-C00028.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00028.MOL SYSTEM "US20030004337A1-20030102-C00028.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00028.TIF SYSTEM "US20030004337A1-20030102-C00028.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00029.CDX SYSTEM "US20030004337A1-20030102-C00029.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00029.MOL SYSTEM "US20030004337A1-20030102-C00029.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00029.TIF SYSTEM "US20030004337A1-20030102-C00029.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00030.CDX SYSTEM "US20030004337A1-20030102-C00030.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00030.MOL SYSTEM "US20030004337A1-20030102-C00030.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00030.TIF SYSTEM "US20030004337A1-20030102-C00030.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00031.CDX SYSTEM "US20030004337A1-20030102-C00031.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00031.MOL SYSTEM "US20030004337A1-20030102-C00031.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00031.TIF SYSTEM "US20030004337A1-20030102-C00031.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00032.CDX SYSTEM "US20030004337A1-20030102-C00032.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00032.MOL SYSTEM "US20030004337A1-20030102-C00032.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00032.TIF SYSTEM "US20030004337A1-20030102-C00032.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00033.CDX SYSTEM "US20030004337A1-20030102-C00033.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00033.MOL SYSTEM "US20030004337A1-20030102-C00033.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00033.TIF SYSTEM "US20030004337A1-20030102-C00033.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00034.CDX SYSTEM "US20030004337A1-20030102-C00034.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00034.MOL SYSTEM "US20030004337A1-20030102-C00034.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00034.TIF SYSTEM "US20030004337A1-20030102-C00034.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00035.CDX SYSTEM "US20030004337A1-20030102-C00035.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00035.MOL SYSTEM "US20030004337A1-20030102-C00035.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00035.TIF SYSTEM "US20030004337A1-20030102-C00035.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00036.CDX SYSTEM "US20030004337A1-20030102-C00036.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00036.MOL SYSTEM "US20030004337A1-20030102-C00036.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00036.TIF SYSTEM "US20030004337A1-20030102-C00036.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00037.CDX SYSTEM "US20030004337A1-20030102-C00037.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00037.MOL SYSTEM "US20030004337A1-20030102-C00037.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00037.TIF SYSTEM "US20030004337A1-20030102-C00037.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00038.CDX SYSTEM "US20030004337A1-20030102-C00038.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00038.MOL SYSTEM "US20030004337A1-20030102-C00038.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00038.TIF SYSTEM "US20030004337A1-20030102-C00038.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00039.CDX SYSTEM "US20030004337A1-20030102-C00039.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00039.MOL SYSTEM "US20030004337A1-20030102-C00039.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00039.TIF SYSTEM "US20030004337A1-20030102-C00039.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00040.CDX SYSTEM "US20030004337A1-20030102-C00040.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00040.MOL SYSTEM "US20030004337A1-20030102-C00040.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00040.TIF SYSTEM "US20030004337A1-20030102-C00040.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00041.CDX SYSTEM "US20030004337A1-20030102-C00041.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00041.MOL SYSTEM "US20030004337A1-20030102-C00041.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00041.TIF SYSTEM "US20030004337A1-20030102-C00041.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00042.CDX SYSTEM "US20030004337A1-20030102-C00042.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00042.MOL SYSTEM "US20030004337A1-20030102-C00042.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00042.TIF SYSTEM "US20030004337A1-20030102-C00042.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00043.CDX SYSTEM "US20030004337A1-20030102-C00043.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00043.MOL SYSTEM "US20030004337A1-20030102-C00043.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00043.TIF SYSTEM "US20030004337A1-20030102-C00043.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00044.CDX SYSTEM "US20030004337A1-20030102-C00044.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00044.MOL SYSTEM "US20030004337A1-20030102-C00044.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00044.TIF SYSTEM "US20030004337A1-20030102-C00044.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00045.CDX SYSTEM "US20030004337A1-20030102-C00045.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00045.MOL SYSTEM "US20030004337A1-20030102-C00045.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00045.TIF SYSTEM "US20030004337A1-20030102-C00045.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00046.CDX SYSTEM "US20030004337A1-20030102-C00046.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00046.MOL SYSTEM "US20030004337A1-20030102-C00046.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00046.TIF SYSTEM "US20030004337A1-20030102-C00046.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00047.CDX SYSTEM "US20030004337A1-20030102-C00047.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00047.MOL SYSTEM "US20030004337A1-20030102-C00047.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00047.TIF SYSTEM "US20030004337A1-20030102-C00047.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00048.CDX SYSTEM "US20030004337A1-20030102-C00048.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00048.MOL SYSTEM "US20030004337A1-20030102-C00048.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00048.TIF SYSTEM "US20030004337A1-20030102-C00048.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00049.CDX SYSTEM "US20030004337A1-20030102-C00049.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00049.MOL SYSTEM "US20030004337A1-20030102-C00049.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00049.TIF SYSTEM "US20030004337A1-20030102-C00049.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00050.CDX SYSTEM "US20030004337A1-20030102-C00050.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00050.MOL SYSTEM "US20030004337A1-20030102-C00050.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00050.TIF SYSTEM "US20030004337A1-20030102-C00050.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00051.CDX SYSTEM "US20030004337A1-20030102-C00051.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00051.MOL SYSTEM "US20030004337A1-20030102-C00051.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00051.TIF SYSTEM "US20030004337A1-20030102-C00051.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00052.CDX SYSTEM "US20030004337A1-20030102-C00052.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00052.MOL SYSTEM "US20030004337A1-20030102-C00052.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00052.TIF SYSTEM "US20030004337A1-20030102-C00052.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00053.CDX SYSTEM "US20030004337A1-20030102-C00053.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00053.MOL SYSTEM "US20030004337A1-20030102-C00053.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00053.TIF SYSTEM "US20030004337A1-20030102-C00053.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00054.CDX SYSTEM "US20030004337A1-20030102-C00054.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00054.MOL SYSTEM "US20030004337A1-20030102-C00054.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00054.TIF SYSTEM "US20030004337A1-20030102-C00054.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00055.CDX SYSTEM "US20030004337A1-20030102-C00055.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00055.MOL SYSTEM "US20030004337A1-20030102-C00055.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00055.TIF SYSTEM "US20030004337A1-20030102-C00055.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00056.CDX SYSTEM "US20030004337A1-20030102-C00056.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00056.MOL SYSTEM "US20030004337A1-20030102-C00056.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00056.TIF SYSTEM "US20030004337A1-20030102-C00056.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00057.CDX SYSTEM "US20030004337A1-20030102-C00057.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00057.MOL SYSTEM "US20030004337A1-20030102-C00057.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00057.TIF SYSTEM "US20030004337A1-20030102-C00057.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00058.CDX SYSTEM "US20030004337A1-20030102-C00058.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00058.MOL SYSTEM "US20030004337A1-20030102-C00058.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00058.TIF SYSTEM "US20030004337A1-20030102-C00058.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00059.CDX SYSTEM "US20030004337A1-20030102-C00059.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00059.MOL SYSTEM "US20030004337A1-20030102-C00059.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00059.TIF SYSTEM "US20030004337A1-20030102-C00059.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00060.CDX SYSTEM "US20030004337A1-20030102-C00060.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00060.MOL SYSTEM "US20030004337A1-20030102-C00060.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00060.TIF SYSTEM "US20030004337A1-20030102-C00060.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00061.CDX SYSTEM "US20030004337A1-20030102-C00061.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00061.MOL SYSTEM "US20030004337A1-20030102-C00061.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00061.TIF SYSTEM "US20030004337A1-20030102-C00061.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00062.CDX SYSTEM "US20030004337A1-20030102-C00062.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00062.MOL SYSTEM "US20030004337A1-20030102-C00062.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00062.TIF SYSTEM "US20030004337A1-20030102-C00062.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-C00063.CDX SYSTEM "US20030004337A1-20030102-C00063.CDX" NDATA CDX>
<!ENTITY US20030004337A1-20030102-C00063.MOL SYSTEM "US20030004337A1-20030102-C00063.MOL" NDATA MOL>
<!ENTITY US20030004337A1-20030102-C00063.TIF SYSTEM "US20030004337A1-20030102-C00063.TIF" NDATA TIF>
<!ENTITY US20030004337A1-20030102-D00001.TIF SYSTEM "US20030004337A1-20030102-D00001.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030004337</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>09848268</doc-number>
</application-number>
<application-number-series-code>09</application-number-series-code>
<filing-date>20010504</filing-date>
</domestic-filing-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>C07D265/32</ipc>
</classification-ipc-primary>
<classification-ipc-secondary>
<ipc>C07D263/18</ipc>
</classification-ipc-secondary>
<classification-ipc-secondary>
<ipc>C07D487/08</ipc>
</classification-ipc-secondary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>540</class>
<subclass>347000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>540</class>
<subclass>607000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>544</class>
<subclass>170000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>548</class>
<subclass>225000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>546</class>
<subclass>216000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Efficient lactam synthesis</title-of-invention>
</technical-information>
<continuity-data>
<non-provisional-of-provisional>
<document-id>
<doc-number>60201734</doc-number>
<document-date>20000504</document-date>
<country-code>US</country-code>
</document-id>
</non-provisional-of-provisional>
</continuity-data>
<inventors>
<first-named-inventor>
<name>
<given-name>Kyung</given-name>
<middle-name>Woon</middle-name>
<family-name>Jung</family-name>
</name>
<residence>
<residence-us>
<city>Tampa</city>
<state>FL</state>
<country-code>US</country-code>
</residence-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Cheol</given-name>
<middle-name>Hwan</middle-name>
<family-name>Yoon</family-name>
</name>
<residence>
<residence-us>
<city>Tampa</city>
<state>FL</state>
<country-code>US</country-code>
</residence-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<correspondence-address>
<name-1>PEPPER, HAMILTON LLP</name-1>
<name-2></name-2>
<address>
<address-1>600 Fourteenth Street, N.W.</address-1>
<city>Washington</city>
<state>DC</state>
<postalcode>20005-2004</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">Lactams, libraries of lactams, and an efficient method of synthesizing a lactam, including a &ggr;-lactam, in which an a-diazoacetamide of the general structure (I) is reacted under conditions promoting intramolecular C-H insertion, for example in the presence of a rhodium salt such as Rh<highlight><subscript>2</subscript></highlight>(OAc)<highlight><subscript>4</subscript></highlight>,  
<chemistry-cwu id="CHEM-US-00001">
<number>1</number>
<image id="EMI-C00001" he="79.91865" wi="158.4198" file="US20030004337A1-20030102-C00001.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00001" file="US20030004337A1-20030102-C00001.CDX"/>
<chemistry-mol-file id="CHEMMOL-00001" file="US20030004337A1-20030102-C00001.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="A-0002" lvl="7">by which means lactams that are precursors in the synthesis of diverse natural and synthetic products, including pyrrolidinone compounds such as lactacystin, pramanicin, kainic acid, statine, AHPPA, and rolipram, are produced. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<section>
<heading lvl="1">RELATED APPLICATIONS </heading>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> The present application is related to U.S. Provisional Application 60/201,734, filed May 4, 2000, which is incorporated herein by reference in its entirety. </paragraph>
</section>
<section>
<heading lvl="1">FIELD OF THE INVENTION </heading>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> The present invention relates generally to synthetic methods for the preparation of lactams. More particularly, the present invention relates to efficient and economic synthetic methods for the preparation of optionally substituted lactams by intramolecular C-H insertion reactions of a-diazoamides, in which the a-diazoamides are activated for intramolecular C-H insertion, for example by sulfone substitution, and to compounds and libraries of compounds derived therefrom. </paragraph>
</section>
<section>
<heading lvl="1">BACKGROUND OF THE INVENTION </heading>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Lactacystin, an exemplary chiral pyrrolidinone, possesses structural motifs common to a number of biologically active natural products such as kainic acid and epolactaene. These molecules, or their synthetic precursors, contain lactam cores (specifically, &ggr;-lactam cores) that are highly functionalized. Numerous medicinal applications of such &ggr;-lactam systems are known, encompassing applications as diverse as, for example, anticancer agents, psychotropic agents, neuromuscular transmission blockers, immunoregulators, neurological excitants, protease inhibitors, and antidepressants. Therefore, a general, efficient and economic synthesis of such chiral pyrrolidinones would facilitate ongoing and future health related research. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> The pyrrolidinone functionality is a prevalent theme in various syntheses, and serves as a crucial intermediate in the synthesis of numerous natural products. Although a large number of synthetic methods have been reported to date (see, for example, DiCosimo, R., Gavagan, J. E., Fager, S. K., Fallon, R. D., Folsom, P. W., Herkes, F. E., Eisenberg, A., and Hann, E. C. &ldquo;Chemoenzymatic Production of Lactams from Aliphatic &agr;,&ohgr;-Dinitriles&rdquo; 1998, J. Org. Chem. 63:4792), the reported asymmetric syntheses are inefficient, lengthy, and costly (see, for example, Meyers, A. I. and Burgess, L. E. &ldquo;Asymmetric Synthesis of &ggr;,&ggr;-Dialkyl-&ggr;-aminobutyric Acid Analogues and 2,2-Disubstituted Pyrrolidines&rdquo; 1991, J. Am. Chem. Soc. 113:9858) </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> Due to their biological activities and interesting structural features, it is also desirable to develop improved synthesis of lactacystin and clasto-lactacystin &bgr;-lactone. New methodology for the construction of the lactam core in order to carry out targeted synthesis efficiently is also desirable. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> For example, the biological activity of lactacystin and clasto-lactacystin &bgr;-lactone (<cross-reference target="DRAWINGS">FIG. 1</cross-reference>), is relevant to the regulation of apoptosis, an active research area for the development of anti-cancer treatments. The process of apoptosis (programmed cell death), which is regulated by the oncoprotein Bcl-2, is targeted through the inhibition of the 20S proteasome, which overcomes the Bcl-2 protective function and thereby induce cell death. Thus, specific inhibition of the 20S proteasome has been proposed for the selective destruction of cancerous cells but not normal cells. As a well-known specific inhibitor of the targeted proteasome, lactacystin has attracted considerable attention from synthetic chemists. Lactacystin is a natural product obtained from microbial metabolites, which induces neurite outgrowth in neuroblastoma cells as well as inhibits progression of human osteosarcoma cells. This natural product and its analog, clasto-lactacystin &bgr;-lactone, also induce apoptosis in human monoblast cells. Because of scarcity and significant bioactivity, there is a need for economic total syntheses of these chiral pyrrolidinone compounds. </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> For synthesis of such chiral pyrrolidinones, amino acids are potential versatile starting materials. To effect the chiral pyrrolidinone synthesis, these amino acids require a ring closure reaction. In one approach, intramolecular C-H insertion reactions of &agr;-diazoamide are used, catalyzed by rhodium salts. However, &agr;-diazoamides are poor substrates in ring closures through C-H insertions, mainly due to competing side reactions, poor regioselectivities, and poor stereoselectivities (Table 1).  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="105PT" align="left"/>
<colspec colname="2" colwidth="112PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry>
<chemistry-cwu id="CHEM-US-00002">
<number>2</number>
<image id="EMI-C00002" he="54.7155" wi="110.65005" file="US20030004337A1-20030102-C00002.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00002" file="US20030004337A1-20030102-C00002.CDX"/>
<chemistry-mol-file id="CHEMMOL-00002" file="US20030004337A1-20030102-C00002.MOL"/>
</chemistry-cwu>
</entry>
<entry>
<chemistry-cwu id="CHEM-US-00003">
<number>3</number>
<image id="EMI-C00003" he="51.597" wi="99.13995" file="US20030004337A1-20030102-C00003.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00003" file="US20030004337A1-20030102-C00003.CDX"/>
<chemistry-mol-file id="CHEMMOL-00003" file="US20030004337A1-20030102-C00003.MOL"/>
</chemistry-cwu>
</entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="56PT" align="center"/>
<colspec colname="2" colwidth="49PT" align="center"/>
<colspec colname="3" colwidth="49PT" align="center"/>
<colspec colname="4" colwidth="63PT" align="left"/>
<tbody valign="top">
<row>
<entry>R<highlight><superscript>1</superscript></highlight></entry>
<entry>R<highlight><superscript>2</superscript></highlight></entry>
<entry>Z</entry>
<entry>Yield(7:8)</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>89% (&gt;99:&lt;1)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry>H</entry>
<entry>95% (81:19)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>92% (37:63)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>H</entry>
<entry>95% (&lt;1:&gt;99)</entry>
</row>
<row>
<entry>PMP</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>CO<highlight><subscript>2</subscript></highlight>Me</entry>
<entry>76% (8:92)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>94% (49:51)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>H</entry>
<entry>85% (&lt;1:32)</entry>
</row>
<row>
<entry>PMP</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>CO<highlight><subscript>2</subscript></highlight>Me</entry>
<entry>84% (&lt;1:&gt;99)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>89% (&gt;99:&lt;1)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry><highlight><superscript>i</superscript></highlight>Pr</entry>
<entry>H</entry>
<entry>95% (81:19)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>92% (37:63)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>H</entry>
<entry>95% (&lt;1:&gt;99)</entry>
</row>
<row>
<entry>PMP</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>CO<highlight><subscript>2</subscript></highlight>Me</entry>
<entry>76% (8:92)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>CH<highlight><subscript>3</subscript></highlight>CO</entry>
<entry>94% (49:51)</entry>
</row>
<row>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>H</entry>
<entry>85% (&lt;1:32)</entry>
</row>
<row>
<entry>PMP</entry>
<entry>PhCH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight></entry>
<entry>CO<highlight><subscript>2</subscript></highlight>Me</entry>
<entry>84% (&lt;1:&gt;99)</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> Common alternative methods employ the use of &agr;-diazoacetamides, &agr;-diazoacetoacetamides, and &agr;-diaomalonamides, which also give rise to regiochemical mixtures. Such reactions are performed at elevated temperature, and often provide low diastereoselectivities. Thus, each reaction gives poor yields and/or a complicated mixture of products, as illustrated below in Scheme A:  
<chemistry-cwu id="CHEM-US-00004">
<number>4</number>
<image id="EMI-C00004" he="303.14655" wi="212.65335" file="US20030004337A1-20030102-C00004.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00004" file="US20030004337A1-20030102-C00004.CDX"/>
<chemistry-mol-file id="CHEMMOL-00004" file="US20030004337A1-20030102-C00004.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> Accordingly, a general synthetic method is desired that affords optionally substituted lactams in high yield, using economical conditions and reagents, comprising synthetic steps that cleanly provide product having the correct stereochemistry. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> In addition, synthetic methods are also desired that economically provide libraries of chemically distinct lactams or compounds derived by further synthesis from lactams, for use, for example, in screening to identify biologically active lead compounds. </paragraph>
</section>
<section>
<heading lvl="1">SUMMARY OF THE INVENTION </heading>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> It is therefore a feature and advantage of the present invention, for example, to provide de novo methodology for the synthesis of the lactam core embedded in lactacystin and to refine this technology for general use. As depicted, for example, below, the C-H insertion reaction of diazo compound <highlight><bold>4</bold></highlight> can lead to the formation of a &ggr;-lactam, which is functionalized at every center. By varying substituents and structures, this method is expanded to formulate a large library of biologically significant lactams and compounds derived therefrom by further synthesis.  
<chemistry-cwu id="CHEM-US-00005">
<number>5</number>
<image id="EMI-C00005" he="169.7031" wi="212.65335" file="US20030004337A1-20030102-C00005.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00005" file="US20030004337A1-20030102-C00005.CDX"/>
<chemistry-mol-file id="CHEMMOL-00005" file="US20030004337A1-20030102-C00005.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> It is another feature and advantage of the present invention to provide the synthetic plan described retrosynthetically in Scheme B. Lactacystin is prepared from bicyclic lactam <highlight><bold>3</bold></highlight> through sequential alkylation and aldol condensation, and pyrrolidinone <highlight><bold>3</bold></highlight> is synthesized by employing the aforementioned method. Several representative syntheses will be elaborated upon in this disclosure. </paragraph>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> It is a further objective of the present invention to utilize expeditious synthesis of highly substituted &ggr;-lactams and other lactams in an asymmetric manner. These cyclization products are for the total synthesis of numerous natural products and new compounds. </paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> It is a further object of the prevent invention to provide a means for synthesis bioactive compounds including, but not limited to, pramanicin, statine, AHPPA, kainic acid, rolipram, and eoplactaene. </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> The above and other features and advantages are achieved through the use of a novel synthetic method as herein disclosed. In accordance with one embodiment of the present invention, there is provided a method of synthesizing a lactam, the method comprising firstly providing an &agr;-diazoacetamide of structure (I),  
<chemistry-cwu id="CHEM-US-00006">
<number>6</number>
<image id="EMI-C00006" he="79.91865" wi="158.4198" file="US20030004337A1-20030102-C00006.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00006" file="US20030004337A1-20030102-C00006.CDX"/>
<chemistry-mol-file id="CHEMMOL-00006" file="US20030004337A1-20030102-C00006.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0016" lvl="7"><number>&lsqb;0016&rsqb;</number> in which R<highlight><subscript>1-6 </subscript></highlight>are substituents that can include H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl; or R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, &mdash;(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;, &mdash;(CH<highlight><subscript>2</subscript></highlight>)<highlight><subscript>n</subscript></highlight>&mdash;O&mdash;C(O)&mdash;, or &mdash;C(X)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;, where n&equals;0-10, and X is (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl or (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl. Secondly, the &agr;-diazoacetamide is reacted under conditions that promote intramolecular C-H insertion, whereby a lactam is synthesized. </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> In accordance with another embodiment of the present invention, lactams synthesized by the foregoing method are provided. An exemplary lactam compound synthesized according to the method of the present invention is clasto-lactacystin &bgr;-lactone. </paragraph>
<paragraph id="P-0018" lvl="0"><number>&lsqb;0018&rsqb;</number> In accordance with another embodiment of the present invention, a library of lactams synthesized by the foregoing method is provided, where such a library may be used, for example, in to screen for compounds having a desired biological activity. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> In accordance with yet another embodiment of the present invention, there is provided a compound synthesized from a lactam synthesized by the method of the present invention. Thus, a variety of natural and other compounds are provided that are synthesized using a lactam produced by the method of the present invention. Exemplary compounds, for which facile synthetic routes can be devised starting from suitable lactams produced according to the present invention, include, but are not limited to lactacystin, pramanicin, kainic acid, statine, AHPPA, rolipram, and salts and enantiomers thereof. </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> There has thus been outlined, rather broadly, the more important features of the invention in order that the detailed description thereof that follows may be better understood, and in order that the present contribution to the art may be better appreciated. There are, of course, additional features of the invention that will be described below and which will form the subject matter of the claims appended hereto. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> In this respect, before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of the method and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways, Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract included below, are for the purpose of description and should not be regarded as limiting. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> As such, those skilled in the art will appreciate that the conception upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.</paragraph>
</section>
</summary-of-invention>
<brief-description-of-drawings>
<section>
<heading lvl="1">BRIEF DESCRIPTION OF THE FIGURE </heading>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 1</cross-reference> Illustrates exemplary medicinal pyrrolidinone compounds that are prepared utilizing the lactams and methods of the present invention.</paragraph>
</section>
</brief-description-of-drawings>
<detailed-description>
<section>
<heading lvl="1">DETAILED DESCRIPTION </heading>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> The present invention provides a method of synthesizing a lactam, including &ggr;-lactams, by a method in which an &agr;-diazoacetamide is reacted under conditions promoting intramolecular C-H insertion. </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> The term &agr;-diazoacetamide as used herein includes compounds of structure (I):  
<chemistry-cwu id="CHEM-US-00007">
<number>7</number>
<image id="EMI-C00007" he="79.91865" wi="158.4198" file="US20030004337A1-20030102-C00007.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00007" file="US20030004337A1-20030102-C00007.CDX"/>
<chemistry-mol-file id="CHEMMOL-00007" file="US20030004337A1-20030102-C00007.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> Where R<highlight><subscript>1</subscript></highlight>, R<highlight><subscript>4</subscript></highlight>, R<highlight><subscript>5</subscript></highlight>, and R<highlight><subscript>6 </subscript></highlight>are, for example, independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, where these substituents have the meaning attributed to them herein below. </paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> In preferred embodiments, R<highlight><subscript>1 </subscript></highlight>is phenyl. </paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> In certain embodiments, such as those directed to the synthesis of compounds comprising a pyrrolidinone functionality, R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>form a ring structure in which R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, &mdash;CH(OH)&mdash;CH(CH<highlight><subscript>3</subscript></highlight>)&mdash;C(O)&mdash;, &mdash;C(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;, &mdash;(CH<highlight><subscript>2</subscript></highlight>)<highlight><subscript>n</subscript></highlight>&mdash;O&mdash;C(O)&mdash;, or C(X)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;, where n&equals;0-10, and X is (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl or (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl. </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> Embodiments directed to the synthesis of compounds comprising a pyrrolidinone functionality include lactam compounds synthesized according to the present invention, which are herein termed &ldquo;pyrrolidinone precursor&rdquo; compounds. Such compounds are lactams that have utility in further synthesis using techniques known to those of skill in the art to produce pyrrolidinone containing compounds. Examples of such pyrrolidinones, from which lactam &ldquo;pyrrolidinone precursor&rdquo; compounds can be derived by retrosynthesis, include, but are not limited to lactacystin, pramanicin, kainic acid, statine, AHPPA, rolipram, or a salts or enantiomers of these compounds. </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> In certain other embodiments, such as those directed to the synthesis of compounds comprising a monocyclic lactam, R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>do not form a ring structure and R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>are independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl. </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> The simplified lactam synthesis of the present invention is further directed to production of libraries of lactam compounds, which, for example, can be screened by a suitable assay for a desired biological activity, or can be subjected to further chemical synthetic steps to generate a library of, for example, analogues of pyrrolidinones such as lactacystin, pramanicin, kainic acid, statine, AHPPA, or rolipram. </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> In promoting intramolecular C-H insertion reactions, which are amply illustrated by the examples herein, certain embodiments comprise the addition of an effective amount of a rhodium salt. In preferred embodiments rhodium tetra-acetate, Rh<highlight><subscript>2</subscript></highlight>(OAc)<highlight><subscript>4,</subscript></highlight>, is used to promote intramolecular C-H insertion reactions. </paragraph>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> The following definitions are used, unless otherwise described. &ldquo;Halo&rdquo; is fluoro, chloro, bromo, or iodo. &ldquo;Alkyl,&rdquo; &ldquo;alkoxy,&rdquo; etc. denote both straight and branched groups; but reference to an individual radical such as &ldquo;propyl&rdquo; embraces only the straight chain radical, a branched chain isomer such as &ldquo;isopropyl&rdquo; being specifically referred to. &ldquo;Aryl&rdquo; denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. &ldquo;Cycloalkyl&rdquo; comprises hydrocarbon ring compounds having between about 3 and 8 ring carbons that are non-aromatic. &ldquo;Alkenyl&rdquo; comprises non-cyclic carbon chains having at least one unsaturated bond. &ldquo;Cycloalkenyl&rdquo; comprises cyclic carbon chains having between about 5 and 8 carbon atoms and having at least one unsaturated bond. &ldquo;Aralkyl&rdquo; comprises an aryl radical attached to an alkyl radical, whereby the combined radicals have between about 7 and 32 carbons and the aryl portion is attached at the position indicated. &ldquo;Alkylaryl&rdquo; comprises an alkyl radical attached to an aryl radical, whereby the combined radicals have between about 7 and 32 carbons and the alkyl portion is attached at the position indicated. &ldquo;Aralkenyl&rdquo; comprises an aryl radical attached to an alkenyl radical, whereby the combined radicals have between about 9 and 32 carbons and the aryl portion is attached at the position indicated. &ldquo;Alkenylaryl&rdquo; comprises an alkenyl radical attached to an aryl radical, whereby the combined radicals have between about 9 and 32 carbons and the alkenyl portion is attached at the position indicated. </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> It will be appreciated by those skilled in the art that compounds of the invention having one or more chiral center(s) may exist in and be isolated in optically active and/or racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase). </paragraph>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents. </paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> Specifically, &ldquo;(C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl&rdquo; can include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl or pentadecyl. &ldquo;(C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>) alkenyl&rdquo; can include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl; 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, 11-dodecenyl, 1-tridecenyl, 2-tridecenyl, 3-tridecenyl, 4-tridecenyl, 5-tridecenyl, 6-tridecenyl, 7-tridecenyl, 8-tridecenyl, 9-tridecenyl, 10-tridecenyl, 11-tridecenyl, 12-tridecenyl, 1-tetradecenyl, 2-tetradecenyl, 3-tetradecenyl, 4-tetradecenyl, 5-tetradecenyl, 6-tetradecenyl 7-tetradecenyl, 8-tetradecenyl, 9-tetradecenyl, 10-tetradecenyl, 11-tetradecenyl, 12-tetradecenyl, 13-tetradecenyl, 1-pentadecenyl, 2-pentadecenyl, 3-pentadecenyl, 4-pentadecenyl, 5-pentadecenyl, 6-pentadecenyl, 7-pentadecenyl, 8-pentadecenyl, 9-pentadecenyl, 10-pentadecenyl, 1 -pentadecenyl, 12-pentadecenyl, 13-pentadecenyl, 14-pentadecenyl. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> &ldquo;(C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl&rdquo; can include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. </paragraph>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> &ldquo;(C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)Aryl&rdquo; encompasses substituted and unsubstituted compounds, and can include phenyl, indenyl, 5,6,7,8-tetrahydronaphthyl, or naphthyl. Substituents include, but are not limited to, H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, OR, SR, N(R<highlight><subscript>2</subscript></highlight>), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, CF<highlight><subscript>3</subscript></highlight>, S(O)R, and SO<highlight><subscript>2</subscript></highlight>R; wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, and (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl. </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> The aforementioned substituents are each optionally substituted with one or more substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkenyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkynyl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl(C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkyl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl-(C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkenyl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>) cycloalkyl(C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>) alkynyl, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkoxy, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>) alkanoyl, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>15</subscript></highlight>)alkanoyloxy, C(&boxH;O)OR, C(&boxH;O)NR<highlight><subscript>2</subscript></highlight>, OC(&boxH;O)OR, OC(&boxH;O)NR<highlight><subscript>2</subscript></highlight>. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> PHENYLSULFONE &agr;-DIAZOAMIDES </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> Regarding the chiral pyrrolidinones, natural and unnatural amino acids represent versatile and economical starting materials. However, the amino acids require at some stage of lactam synthesis, a ring closure reaction. Within the scope of the present invention, the intramolecular C-H insertion reaction of certain &agr;-diazoamides, synthesized for example from such amino acids, affords the corresponding &ggr;-lactam. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> Studies related to mechanistic pathways involved in intramolecular C-H insertion of diazoamides of the present invention show that ring closure through a C-H insertion is efficient and selective. The present invention therefore not only provides an efficient method, but also offers solutions to the existing problems in carbenoid insertion using amides. A variety of new chiral templates can be created and implemented in numerous asymmetric syntheses, as illustrated herein. </paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number> One embodiment of the present invention comprises the use of &agr;-diazoamides with steric and stereoelectronic variations. For example, a sulfonylacetamide is employed to alter electron density as well as steric constraints in such a way, and without being limited thereby by theory, to enhance the reactivity of the incipient rhodium carbenoid and increase regio- and stereoselectivities. As shown in Scheme D, cyclization precursors <highlight><bold>9</bold></highlight> and <highlight><bold>12</bold></highlight> are prepared from serine and phenylalanine, respectively, and are subjected to rhodium (ii) mediated C-H insertion catalysis.  
<chemistry-cwu id="CHEM-US-00008">
<number>8</number>
<image id="EMI-C00008" he="452.21085" wi="212.42655" file="US20030004337A1-20030102-C00008.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00008" file="US20030004337A1-20030102-C00008.CDX"/>
<chemistry-mol-file id="CHEMMOL-00008" file="US20030004337A1-20030102-C00008.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> Advantageously, diazo compound <highlight><bold>9</bold></highlight> is smoothly converted to the desired lactam <highlight><bold>10</bold></highlight> in 97% yield at room temperature. The reaction proceeds more quickly under reflux of dichloromethane, and negligable regioisomers are detected. 1,2-Asymmetric induction is specific to give the silyl group in the convex face, while 1,3-induction is greater than 20:1, favoring the syn conformation to the neighboring silyl ether. The stereochemistry is deduced using NOE and 2D-NMR techniques. With <highlight><bold>12</bold></highlight>, conversion slow at room temperature, whereas ring closure takes place efficiently under reflux and exhibits similar results to those obtained using serine. It should be noted that the lactams thus produced are fully functionalized, and essentially every center can be further manipulated by appropriate syntheses.  
<chemistry-cwu id="CHEM-US-00009">
<number>9</number>
<image id="EMI-C00009" he="182.1771" wi="111.84075" file="US20030004337A1-20030102-C00009.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00009" file="US20030004337A1-20030102-C00009.CDX"/>
<chemistry-mol-file id="CHEMMOL-00009" file="US20030004337A1-20030102-C00009.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> Not to be limited by theory, the observed stereochemical outcomes conform to hypothesized transition states, such as are compared for illustrative purposes only in Scheme E. 1,2-Asymmetric induction, stemming from the amino acid, suggests two possible transition states <highlight><bold>14</bold></highlight> and <highlight><bold>15</bold></highlight>, wherein the silyl group is located in either the pseudo-equatorial or the pseudo-axial position, respectively. The latter case produced a severe 1,3-diaxial non-bonded interaction, whereas in the former case the molecule adopts a stable chair-like transition state with large groups in the equatorial positions. The phenylsulfone group is rationalized from the observed stereochemistry of products to be in the equatorial position. </paragraph>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number> These methods are extended to various substrates below to demonstrate the efficacy of the present invention and the high degree of stereoselectivity obtained. Although these examples focus mainly on amino acid-derived substrates for the synthesis of various chiral pyrrolidinones and their derivatives, it should be noted that the methods of the present invention are not confined to the use of amino acid substrates, or to only synthesis of pyrrolidinone-containing lactams. </paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> B. FOUR EXEMPLARY ROUTES FOR SYNTHESIS OF &agr;-DIAZOAMIDES FROM AMINO ACIDS </paragraph>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> Prior to the provision of additional specific synthetic examples, four possible embodiments of the present invention are broadly outlined, in the form of four exemplary non-limiting alternative synthetic strategies for lactam synthesis. </paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number> Rhodium(II) Catalyzed Intramolecular C-H Insertion of &agr;-Diazoamides Derived from Amino Acids  
<chemistry-cwu id="CHEM-US-00010">
<number>10</number>
<image id="EMI-C00010" he="243.38475" wi="212.42655" file="US20030004337A1-20030102-C00010.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00010" file="US20030004337A1-20030102-C00010.CDX"/>
<chemistry-mol-file id="CHEMMOL-00010" file="US20030004337A1-20030102-C00010.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number> Method A: Utilization of Cyclic Substrates </paragraph>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> As delineated in Scheme F, one general synthetic route for &agr;-diazoamides is illustrated. Each amino acid is transformed to sulfonamide <highlight><bold>17</bold></highlight> by successive esterification, amide formation, and selective ester reduction. After acetonide formation, a diazo transfer gives rise to the cyclization precursors. Diazo transfer is facile and rapid, requiring only approximately 5 minutes.  
<chemistry-cwu id="CHEM-US-00011">
<number>11</number>
<image id="EMI-C00011" he="379.01115" wi="216.027" file="US20030004337A1-20030102-C00011.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00011" file="US20030004337A1-20030102-C00011.CDX"/>
<chemistry-mol-file id="CHEMMOL-00011" file="US20030004337A1-20030102-C00011.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> The diazo compounds are treated with a rhodium catalyst to produce various bicyclic &ggr;-lactams <highlight><bold>19</bold></highlight>, formed via C-H insertion of <highlight><bold>18</bold></highlight> in a regio- and stereoselective manner. The yields are high, and the ring closure reactions tolerate numerous functionalities, including but not limited to esters and sulfides. Some examples are listed in Scheme G. Difference in reactivities may depend on substituents, which may be exploited in designing the synthesis of structurally complicated natural products. </paragraph>
<paragraph id="P-0053" lvl="0"><number>&lsqb;0053&rsqb;</number> For example, as demonstrated in Scheme D, the hydrogen adjacent to the silyl ether is prone to insertion, while the hydrogen next to a phenyl group is resistant to insertion at room temperature. In general, and without being limited by theory, hydrogens adjacent to heteroatoms are more reactive than those next to alkyl groups. Electron donating groups facilitate the desired conversions, while a silyl directing effect that promotes C-H insertion adjacent to a silyl ether is observed in the serine case (above). </paragraph>
<paragraph id="P-0054" lvl="0"><number>&lsqb;0054&rsqb;</number> Method B: Utilization of Cyclic Carbonyl Substrates </paragraph>
<paragraph id="P-0055" lvl="0"><number>&lsqb;0055&rsqb;</number> Cyclic carbonyl substrates <highlight><bold>21</bold></highlight> are prepared by using a similar reaction sequence (Scheme H) to the previously discussed method. Masking of carboxylic acids is unavoidable during amide formation, and the ensuing hydrolysis secure amino acids <highlight><bold>20</bold></highlight>.  
<chemistry-cwu id="CHEM-US-00012">
<number>12</number>
<image id="EMI-C00012" he="655.5087" wi="215.8002" file="US20030004337A1-20030102-C00012.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00012" file="US20030004337A1-20030102-C00012.CDX"/>
<chemistry-mol-file id="CHEMMOL-00012" file="US20030004337A1-20030102-C00012.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0056" lvl="0"><number>&lsqb;0056&rsqb;</number> Since the oxidation state of each amino acid is preserved by this method, the produced bicyclic lactam <highlight><bold>22</bold></highlight> can be more diverse than lactam <highlight><bold>19</bold></highlight>. For example, in a diazo transfer reaction to make <highlight><bold>21</bold></highlight> with R&equals;benzyl, which stems from phenylalanine, tosyl azide smoothly reacts to provide <highlight><bold>21</bold></highlight>. Method B allows for the production of various cyclic amino esters. </paragraph>
<paragraph id="P-0057" lvl="0"><number>&lsqb;0057&rsqb;</number> Method C: Utilization of Acyclic Substrates  
<chemistry-cwu id="CHEM-US-00013">
<number>13</number>
<image id="EMI-C00013" he="683.1216" wi="216.027" file="US20030004337A1-20030102-C00013.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00013" file="US20030004337A1-20030102-C00013.CDX"/>
<chemistry-mol-file id="CHEMMOL-00013" file="US20030004337A1-20030102-C00013.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0058" lvl="0"><number>&lsqb;0058&rsqb;</number> Since acyclic amino esters may undergo side reactions during diazo transfer, it is advantageous to utilize reduced substrates for diazoamide in Scheme I. After the synthesis of amino acid methyl esters, chemoselective mono N-alkylation is carried out (see, Salvatore, R. N., et al., &ldquo;Cesium Hydroxide Promoted Chemoselective N-Alkylation for the Generally Efficient Synthesis of Secondary Amines&rdquo; Org. Lett., 1999, vol.1, p. 1893), which is followed by amide formation to give <highlight><bold>23</bold></highlight>. Selective reduction of the ester, silylation and diazo transfer generate acyclic diazo substrates <highlight><bold>24</bold></highlight>. </paragraph>
<paragraph id="P-0059" lvl="0"><number>&lsqb;0059&rsqb;</number> The C-H insertion reactions undertaken with substrates highlighted in Scheme I, illustrate certain useful aspects. First, regioselectivity and stereoselectivity are excellent, illustrating the generality of the methodology. Five membered lactams are exclusively produced, while the anti selectivities in both 1,2- and 1,3-asymmetric inductions are predominant, possible due to placement of all three substituents in pseudo-equatorial positions. </paragraph>
<paragraph id="P-0060" lvl="0"><number>&lsqb;0060&rsqb;</number> The first four substrates denoted in Scheme I compare alkyl versus silyl ether groups, among which the silyl group will control the regioselectivity as rationalized above. By employing the substrate <highlight><bold>24</bold></highlight> derived from serine, the silyl group directing effect is unambiguously demonstrated, which is the first demonstration of a &bgr;-silyl effect in C-H insertion of carbenoids. </paragraph>
<paragraph id="P-0061" lvl="0"><number>&lsqb;0061&rsqb;</number> Method D: Utilization of Cyclic Chiral Auxiliaries  
<chemistry-cwu id="CHEM-US-00014">
<number>14</number>
<image id="EMI-C00014" he="229.4649" wi="216.027" file="US20030004337A1-20030102-C00014.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00014" file="US20030004337A1-20030102-C00014.CDX"/>
<chemistry-mol-file id="CHEMMOL-00014" file="US20030004337A1-20030102-C00014.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0062" lvl="0"><number>&lsqb;0062&rsqb;</number> The present invention comprising C-H insertion technologies applies to non-amino acid substrates. In the present method, amino acid moieties are utilized as chiral auxiliaries as shown in Scheme J. Phenylglycinol is converted to amide <highlight><bold>26</bold></highlight>, which is then subjected to the formation of N,O-acetals where the newly generated stereocenter is governed by the pre-existing asymmetric carbon of phenyl glycine. In turn, this new stereogenicity is transferred to the C-H insertion center, mimicking method A. An advantage of this method is the use of a number of substrates, not only limited to amino acids.  
<chemistry-cwu id="CHEM-US-00015">
<number>15</number>
<image id="EMI-C00015" he="672.8022" wi="215.8002" file="US20030004337A1-20030102-C00015.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00015" file="US20030004337A1-20030102-C00015.CDX"/>
<chemistry-mol-file id="CHEMMOL-00015" file="US20030004337A1-20030102-C00015.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0063" lvl="0"><number>&lsqb;0063&rsqb;</number> As delineated in Scheme K, phenylglycine <highlight><bold>29</bold></highlight> is converted to amide <highlight><bold>30</bold></highlight> using the indicated reactions. Oxidation and diazo transfer are free from any practical problems to provide C-H insertion substrate <highlight><bold>32</bold></highlight>. The cyclic substrate <highlight><bold>32</bold></highlight> is structurally reminiscent of the cyclization precursor <highlight><bold>18</bold></highlight> (method A), and similar results are observed. </paragraph>
<paragraph id="P-0064" lvl="0"><number>&lsqb;0064&rsqb;</number> A variety of carbonyl compounds are employed to produce a library of chiral intermediates for synthesis, which can be utilized in drug screening. Carbonyl substituents are comprised of, for example, alkyl, aromatic, and heterocyclic groups, as well as heteroatoms. In addition to this diversity, asymmetric induction at the unactivated carbon is also envisioned as within the scope of the present invention. </paragraph>
<paragraph id="P-0065" lvl="0"><number>&lsqb;0065&rsqb;</number> Numerous variations upon the four basic methods broadly outlined above are possible within the scope of the present invention, as will be better understood upon reading the following examples of lactam syntheses, which are provided for illustrative purposes only and are in nowise limiting. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 1 </heading>
<paragraph id="P-0066" lvl="0"><number>&lsqb;0066&rsqb;</number> &ggr;-Lactam Synthesis from secondary amines </paragraph>
<paragraph id="P-0067" lvl="0"><number>&lsqb;0067&rsqb;</number> Total synthesis of &ggr;-lactam from diverse secondary amines is achieved by the present i invention according to the following scheme:  
<chemistry-cwu id="CHEM-US-00016">
<number>16</number>
<image id="EMI-C00016" he="69.8544" wi="201.6252" file="US20030004337A1-20030102-C00016.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00016" file="US20030004337A1-20030102-C00016.CDX"/>
<chemistry-mol-file id="CHEMMOL-00016" file="US20030004337A1-20030102-C00016.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0068" lvl="7"><number>&lsqb;0068&rsqb;</number> where R<highlight><subscript>1-4 </subscript></highlight>include, independently, for example, halo, alkyl, alkoxy, aryl, cycloalkyl, alkenyl, cycloalkenyl, aralkyl, aralkenyl, alkenylaryl. This Example proceeds firstly by a demonstration of two alternative methods for the preparation of &agr;-phenylsulfonylacetamide; secondly by the synthesis of several &agr;-phenylsulfonyl-&agr;-diazoacetamides (a-g); and thirdly by the synthesis of corresponding &ggr;-lactams via C-H insertion. </paragraph>
<paragraph id="P-0069" lvl="0"><number>&lsqb;0069&rsqb;</number> Preparation of &agr;-phenylsulfonylacetamide </paragraph>
<paragraph id="P-0070" lvl="0"><number>&lsqb;0070&rsqb;</number> Method 1  
<chemistry-cwu id="CHEM-US-00017">
<number>17</number>
<image id="EMI-C00017" he="144.018" wi="212.42655" file="US20030004337A1-20030102-C00017.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00017" file="US20030004337A1-20030102-C00017.CDX"/>
<chemistry-mol-file id="CHEMMOL-00017" file="US20030004337A1-20030102-C00017.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0071" lvl="0"><number>&lsqb;0071&rsqb;</number> To a mixture of secondary amine I and TEA in anhydrous dichloromethane, are added dropwise a solution of phenylthioacetyl chloride (prepared from phenylthioacetic acid and thionyl chloride) in anhydrous dichloromethane at 0&deg; C. The reaction mixture is warmed to room temperature, stirred for 2 hours, then sat&apos;d NH<highlight><subscript>4</subscript></highlight>Cl solution and dichloromethane are added. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and concentrated to afford &agr;-phenylthioacetamide II, which is used for the next reaction without purification. </paragraph>
<paragraph id="P-0072" lvl="0"><number>&lsqb;0072&rsqb;</number> To a solution &agr;-phenylthioacetamide II in anhydrous dichloromethane, is added m-CPBA at 0&deg; C. The reaction mixture is stirred for 1 hour at room temperature and then treated with 1 N NaOH solution. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and evaporated. The residue is purified by silica gel column chromatography to give &agr;-phenylsulfonylacetamide III. </paragraph>
<paragraph id="P-0073" lvl="0"><number>&lsqb;0073&rsqb;</number> Method 2  
<chemistry-cwu id="CHEM-US-00018">
<number>18</number>
<image id="EMI-C00018" he="144.018" wi="212.42655" file="US20030004337A1-20030102-C00018.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00018" file="US20030004337A1-20030102-C00018.CDX"/>
<chemistry-mol-file id="CHEMMOL-00018" file="US20030004337A1-20030102-C00018.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0074" lvl="0"><number>&lsqb;0074&rsqb;</number> To a mixture of secondary amine I and TEA in anhydrous dichloromethane, is added dropwise a solution of bromoacetyl bromide in anhydrous dichloromethane at 0&deg; C. The reaction mixture is warmed to room temperature, stirred for 2 hours, then sat&apos;d NH<highlight><subscript>4</subscript></highlight>Cl solution and dichloromethane are added. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and concentrated to afford &agr;-bromoacetamide IV, which is used for the next reaction without purification. </paragraph>
<paragraph id="P-0075" lvl="0"><number>&lsqb;0075&rsqb;</number> To a solution of &agr;-bromoacetamide IV in anhydrous DMF, is added PhSO<highlight><subscript>2</subscript></highlight>Na at 0&deg; C. The reaction mixture is stirred for 1 hour at room temperature and is then poured into water. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and evaporated. The residue is purified by silica gel column chromatography to give &agr;-phenylsulfonylacetamide III. </paragraph>
<paragraph id="P-0076" lvl="0"><number>&lsqb;0076&rsqb;</number> Preparation of various &agr;-phenylsulfonyl-&agr;-diazoacetamides </paragraph>
<paragraph id="P-0077" lvl="0"><number>&lsqb;0077&rsqb;</number> a. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-1  
<chemistry-cwu id="CHEM-US-00019">
<number>19</number>
<image id="EMI-C00019" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00019.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00019" file="US20030004337A1-20030102-C00019.CDX"/>
<chemistry-mol-file id="CHEMMOL-00019" file="US20030004337A1-20030102-C00019.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0078" lvl="0"><number>&lsqb;0078&rsqb;</number> To a solution of the &agr;-phenylsulfonylacetamide <highlight><bold>1</bold></highlight><highlight><italic>a </italic></highlight>and DBU in anhydrous acetonitrile, is added ABSA (p-N-acetylbenzosulfonylazide). The reaction mixture is stirred for 30 min. at room temperature, then poured into water. The aqueous layer is extracted twice with EtOAc. The combined organic layers are washed with 10% aqueous NaOH solution and brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and then evaporated. The residue is purified by silica gel column chromatography to give (&agr;-diazo-&agr;-phenylsulfonylacetamide as yellow oil. </paragraph>
<paragraph id="P-0079" lvl="0"><number>&lsqb;0079&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>)&dgr;0.05 (s, 3 H), 0.88 (s, 3 H), 1.29 (d, 9 H), 3.69 (m, 4 H), 7.57 (m, 3 H), 7.92 (m, 2 H) </paragraph>
<paragraph id="P-0080" lvl="0"><number>&lsqb;0080&rsqb;</number> b. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-2  
<chemistry-cwu id="CHEM-US-00020">
<number>20</number>
<image id="EMI-C00020" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00020.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00020" file="US20030004337A1-20030102-C00020.CDX"/>
<chemistry-mol-file id="CHEMMOL-00020" file="US20030004337A1-20030102-C00020.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0081" lvl="0"><number>&lsqb;0081&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>2</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide III-<highlight><bold>2</bold></highlight>. </paragraph>
<paragraph id="P-0082" lvl="0"><number>&lsqb;0082&rsqb;</number> c. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>3</bold></highlight>  
<chemistry-cwu id="CHEM-US-00021">
<number>21</number>
<image id="EMI-C00021" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00021.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00021" file="US20030004337A1-20030102-C00021.CDX"/>
<chemistry-mol-file id="CHEMMOL-00021" file="US20030004337A1-20030102-C00021.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0083" lvl="0"><number>&lsqb;0083&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>3</bold></highlight> is obtained from a-phenylsulfonylacetamide III-<highlight><bold>3</bold></highlight>. </paragraph>
<paragraph id="P-0084" lvl="0"><number>&lsqb;0084&rsqb;</number> d. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>4</bold></highlight>  
<chemistry-cwu id="CHEM-US-00022">
<number>22</number>
<image id="EMI-C00022" he="78.72795" wi="210.49875" file="US20030004337A1-20030102-C00022.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00022" file="US20030004337A1-20030102-C00022.CDX"/>
<chemistry-mol-file id="CHEMMOL-00022" file="US20030004337A1-20030102-C00022.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0085" lvl="0"><number>&lsqb;0085&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>4</bold></highlight> is obtained from a-phenylsulfonylacetamide III-<highlight><bold>4</bold></highlight>. </paragraph>
<paragraph id="P-0086" lvl="0"><number>&lsqb;0086&rsqb;</number> e. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>5</bold></highlight>  
<chemistry-cwu id="CHEM-US-00023">
<number>23</number>
<image id="EMI-C00023" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00023.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00023" file="US20030004337A1-20030102-C00023.CDX"/>
<chemistry-mol-file id="CHEMMOL-00023" file="US20030004337A1-20030102-C00023.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0087" lvl="0"><number>&lsqb;0087&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>5</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide III-<highlight><bold>5</bold></highlight>. </paragraph>
<paragraph id="P-0088" lvl="0"><number>&lsqb;0088&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.87 (t, 3 H, J&equals;7.27 Hz), 1.25 (m, 2 H), 1.50 (m, 2 H), 3.23 (t, 2 H, J&equals;7.67 Hz), 4.56 (s, 2 H), 7.24 (m, 5 H), 7.60 (m,, 3 H), 8.02 (m, 2 H) </paragraph>
<paragraph id="P-0089" lvl="0"><number>&lsqb;0089&rsqb;</number> f. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>6</bold></highlight>  
<chemistry-cwu id="CHEM-US-00024">
<number>24</number>
<image id="EMI-C00024" he="160.5744" wi="212.19975" file="US20030004337A1-20030102-C00024.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00024" file="US20030004337A1-20030102-C00024.CDX"/>
<chemistry-mol-file id="CHEMMOL-00024" file="US20030004337A1-20030102-C00024.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0090" lvl="0"><number>&lsqb;0090&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>6</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide III-<highlight><bold>6</bold></highlight>. </paragraph>
<paragraph id="P-0091" lvl="0"><number>&lsqb;0091&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.018 (s, 6 H), 0.84 (s, 9 H), 1.42 (s, 9 H), 2.52 (t, 2 H, J&equals;7.14Hz), 3.49 (t, 2 H, J&equals;5.1 Hz), 3.60 (t, 2 H, J&equals;7.14 Hz), 3.72 (t, 2 H, J&equals;5.1 Hz), 7.59 (m, 3H), 7.99 (d, 2 H, J&equals;7.4 Hz) </paragraph>
<paragraph id="P-0092" lvl="0"><number>&lsqb;0092&rsqb;</number> g. &agr;-Phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>7</bold></highlight>  
<chemistry-cwu id="CHEM-US-00025">
<number>25</number>
<image id="EMI-C00025" he="160.5744" wi="212.42655" file="US20030004337A1-20030102-C00025.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00025" file="US20030004337A1-20030102-C00025.CDX"/>
<chemistry-mol-file id="CHEMMOL-00025" file="US20030004337A1-20030102-C00025.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0093" lvl="0"><number>&lsqb;0093&rsqb;</number> Following the procedure of the preparation of V-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>7</bold></highlight> is obtained from ax-phenylsulfonylacetamide III-<highlight><bold>7</bold></highlight>. </paragraph>
<paragraph id="P-0094" lvl="0"><number>&lsqb;0094&rsqb;</number> The Synthesis of &ggr;-Lactam via C-H Insertion </paragraph>
<paragraph id="P-0095" lvl="0"><number>&lsqb;0095&rsqb;</number> a. &ggr;-Lactam VI-<highlight><bold>1</bold></highlight>  
<chemistry-cwu id="CHEM-US-00026">
<number>26</number>
<image id="EMI-C00026" he="78.50115" wi="212.42655" file="US20030004337A1-20030102-C00026.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00026" file="US20030004337A1-20030102-C00026.CDX"/>
<chemistry-mol-file id="CHEMMOL-00026" file="US20030004337A1-20030102-C00026.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0096" lvl="0"><number>&lsqb;0096&rsqb;</number> To a solution of &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>1</bold></highlight> in dry CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>, is added a catalytic amount of Rh<highlight><subscript>2</subscript></highlight>(OAc)<highlight><subscript>4 </subscript></highlight>The mixture is refluxed with stirring for 12 hours under N<highlight><subscript>2</subscript></highlight>, cooled to room temperature, and is then concentrated. The residue is purified by silica gel column chromatography to give &ggr;-lactam VI-<highlight><bold>1</bold></highlight>. </paragraph>
<paragraph id="P-0097" lvl="0"><number>&lsqb;0097&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.11 (d, 6 H, J&equals;1.8 Hz), 0.86 (s, 9 H), 1.35 (s, 9 H), 3.27 (d, 1 H, J&equals;10.5 Hz), 3.72 (s, 1 H), 3.81 (dd, 1 H, J&equals;10.5, 5.3 Hz), 4.87 (d, 1 H, J&equals;5.3 Hz), 7.58 (m, 5 H). </paragraph>
<paragraph id="P-0098" lvl="0"><number>&lsqb;0098&rsqb;</number> b. &ggr;-Lactam VI-<highlight><bold>2</bold></highlight>  
<chemistry-cwu id="CHEM-US-00027">
<number>27</number>
<image id="EMI-C00027" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00027.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00027" file="US20030004337A1-20030102-C00027.CDX"/>
<chemistry-mol-file id="CHEMMOL-00027" file="US20030004337A1-20030102-C00027.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0099" lvl="0"><number>&lsqb;0099&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &ggr;-lactam VI-<highlight><bold>2</bold></highlight> is obtained from &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>2</bold></highlight>. </paragraph>
<paragraph id="P-0100" lvl="0"><number>&lsqb;0100&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.40 (s, 9 H), 3.5 (dd, 1 H, J&equals;2.0, 9.7 Hz), 3.88 (d, 1 H, J&equals;3.0 Hz), 4.02 (dd, 1 H, J&equals;8.0, 9.7 Hz), 4.09 (ddd, 1 H, J&equals;2.0, 3.0, 8.0 Hz), 7.25 (m, 5 H), 7.58 (m, 3 H), 7.93 (d, 2 H, J&equals;7.4 Hz) </paragraph>
<paragraph id="P-0101" lvl="0"><number>&lsqb;0101&rsqb;</number> c. &ggr;-Lactam VI-<highlight><bold>3</bold></highlight>  
<chemistry-cwu id="CHEM-US-00028">
<number>28</number>
<image id="EMI-C00028" he="78.246" wi="212.42655" file="US20030004337A1-20030102-C00028.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00028" file="US20030004337A1-20030102-C00028.CDX"/>
<chemistry-mol-file id="CHEMMOL-00028" file="US20030004337A1-20030102-C00028.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0102" lvl="0"><number>&lsqb;0102&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &ggr;-lactam VI-<highlight><bold>3</bold></highlight> is obtained from &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>3</bold></highlight>. </paragraph>
<paragraph id="P-0103" lvl="0"><number>&lsqb;0103&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.89 (d, 3 H, J&equals;6.6 Hz), 0.95 (d, 3 H, J&equals;6.5 Hz), 1.31 (s, 3 H), 1.66 (s, 3 H) 1.89 (m, 1 H), 2.95 (m, 2 H), 3.22 (dd, 1 H, J&equals;8.2, 13.3 Hz), 3.55 (s, 1 H), 3.57 (m, 1 H), 7.59 (m,, 3 H), 7.89 (d, 2H, J&equals;7.2 Hz) </paragraph>
<paragraph id="P-0104" lvl="0"><number>&lsqb;0104&rsqb;</number> d. &ggr;-Lactam VI-<highlight><bold>4</bold></highlight>  
<chemistry-cwu id="CHEM-US-00029">
<number>29</number>
<image id="EMI-C00029" he="66.25395" wi="210.49875" file="US20030004337A1-20030102-C00029.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00029" file="US20030004337A1-20030102-C00029.CDX"/>
<chemistry-mol-file id="CHEMMOL-00029" file="US20030004337A1-20030102-C00029.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0105" lvl="0"><number>&lsqb;0105&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &ggr;-lactam VI-<highlight><bold>3</bold></highlight> is obtained from &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>3</bold></highlight>. </paragraph>
<paragraph id="P-0106" lvl="0"><number>&lsqb;0106&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) 2.44 (m, 1 H), 2.73 (m, 1 H), 3.20 (m, 1 H), 3.36 (m, 1 H), 3.94 (dd, 1 H, J&equals;4.2, 10.1 Hz), 4.40 and 4.46 (ABq, 2 H, 15 Hz), 7.25 (m, 5 H), 7.62 (m, 3 H), 7.96 (m, 2 H) </paragraph>
<paragraph id="P-0107" lvl="0"><number>&lsqb;0107&rsqb;</number> d. &ggr;-Lactam VI-<highlight><bold>5</bold></highlight>  
<chemistry-cwu id="CHEM-US-00030">
<number>30</number>
<image id="EMI-C00030" he="78.72795" wi="210.49875" file="US20030004337A1-20030102-C00030.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00030" file="US20030004337A1-20030102-C00030.CDX"/>
<chemistry-mol-file id="CHEMMOL-00030" file="US20030004337A1-20030102-C00030.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0108" lvl="0"><number>&lsqb;0108&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &ggr;-lactam VI-<highlight><bold>5</bold></highlight> is obtained from &agr;-phenylsulfonyl-&agr;-diazoacetamide V-<highlight><bold>5</bold></highlight>. </paragraph>
<paragraph id="P-0109" lvl="0"><number>&lsqb;0109&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.87 (t, 1 H, J&equals;7.3 Hz), 1.48 (m, 1 H), 1.62 (m, 1 H ), 2.87 (dd, 1 H, J&equals;9.1, 3.7 Hz), 3.54 (d, 1 H, J&equals;3.7 Hz), 4.41 (dd, 2 H, J&equals;28.2, 14.8 Hz), 7.57 (m, 10 H); <highlight><superscript>13</superscript></highlight>C NMR (90 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;10.76, 27.77, 33.92, 46.96, 50.10, 71.30, 127.79, 127.93, 128.75, 128.96, 129.33, 134.13, 135.29, 137.78, 165.06. </paragraph>
<paragraph id="P-0110" lvl="0"><number>&lsqb;0110&rsqb;</number> e. &ggr;-Lactam VI-<highlight><bold>6</bold></highlight>  
<chemistry-cwu id="CHEM-US-00031">
<number>31</number>
<image id="EMI-C00031" he="152.89155" wi="211.9446" file="US20030004337A1-20030102-C00031.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00031" file="US20030004337A1-20030102-C00031.CDX"/>
<chemistry-mol-file id="CHEMMOL-00031" file="US20030004337A1-20030102-C00031.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0111" lvl="0"><number>&lsqb;0111&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide VI-<highlight><bold>6</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide V-<highlight><bold>6</bold></highlight>. </paragraph>
<paragraph id="P-0112" lvl="0"><number>&lsqb;0112&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.12 (s, 3 H), 0.13 (s, 3 H), 0.87 (s, 9 H), 1.44 (s, 9 H), 2.47 (t, 2 H, J&equals;6.8 Hz), 3.27 (d, 1 H, J&equals;10.5 Hz), 3.57 (m, 2 H), 3.77 (s, 1 H), 3.82 (dd, 1 H, J&equals;5.5, 10.5 Hz), 4.99 (d, 1 H, J&equals;5.5 Hz), 7.7 (m,, 3H), 7.92 (d, 2 H, J&equals;7.3 Hz) </paragraph>
<paragraph id="P-0113" lvl="0"><number>&lsqb;0113&rsqb;</number> f. &ggr;-Lactam VI-<highlight><bold>7</bold></highlight>  
<chemistry-cwu id="CHEM-US-00032">
<number>32</number>
<image id="EMI-C00032" he="152.89155" wi="211.46265" file="US20030004337A1-20030102-C00032.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00032" file="US20030004337A1-20030102-C00032.CDX"/>
<chemistry-mol-file id="CHEMMOL-00032" file="US20030004337A1-20030102-C00032.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0114" lvl="0"><number>&lsqb;0114&rsqb;</number> Following the procedure of the preparation of VI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide VI-<highlight><bold>7</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide V-<highlight><bold>7</bold></highlight>. </paragraph>
<paragraph id="P-0115" lvl="0"><number>&lsqb;0115&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.25 (t, 3 H, J&equals;7.1 Hz), 2.62 (m, 2 H), 3.50 (dd, 1 H, J&equals;2.5, 10 Hz), 3.66 (dd, I H, J&equals;5.9, 6.8 Hz), 3.93 (d, 1 H, J&equals;3.0 Hz), 4.05 (dd, 1 H, J&equals;8.4, 9.89 Hz), 4.14 (q, 2 H, J&equals;7.1 Hz), 4.20 (m, 1 H), 7.24 (m, 5 H), 7.67 (m, 3 H), 7.92 (d, 2 H, J&equals;7.3 Hz) </paragraph>
<paragraph id="P-0116" lvl="0"><number>&lsqb;0116&rsqb;</number> The results for Example 1 are collected in Table 2:  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 2</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>&ggr;-Lactam Synthesis via C&mdash;H Insertion reaction</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="140PT" align="left"/>
<colspec colname="2" colwidth="77PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry>
<chemistry-cwu id="CHEM-US-00033">
<number>33</number>
<image id="EMI-C00033" he="66.9627" wi="137.0439" file="US20030004337A1-20030102-C00033.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00033" file="US20030004337A1-20030102-C00033.CDX"/>
<chemistry-mol-file id="CHEMMOL-00033" file="US20030004337A1-20030102-C00033.MOL"/>
</chemistry-cwu>
</entry>
<entry>
<chemistry-cwu id="CHEM-US-00034">
<number>34</number>
<image id="EMI-C00034" he="61.43445" wi="75.1275" file="US20030004337A1-20030102-C00034.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00034" file="US20030004337A1-20030102-C00034.CDX"/>
<chemistry-mol-file id="CHEMMOL-00034" file="US20030004337A1-20030102-C00034.MOL"/>
</chemistry-cwu>
</entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="42PT" align="center"/>
<colspec colname="2" colwidth="63PT" align="center"/>
<colspec colname="3" colwidth="49PT" align="center"/>
<colspec colname="4" colwidth="21PT" align="center"/>
<colspec colname="5" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry>entry</entry>
<entry>R<highlight><superscript>2</superscript></highlight></entry>
<entry>R<highlight><superscript>3</superscript></highlight></entry>
<entry>R<highlight><superscript>4</superscript></highlight></entry>
<entry>Yield</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry>1</entry>
<entry><highlight><superscript>t</superscript></highlight>Bu</entry>
<entry>OTBS</entry>
<entry>H</entry>
<entry>93%</entry>
</row>
<row>
<entry>2</entry>
<entry><highlight><superscript>t</superscript></highlight>Bu</entry>
<entry>Ph</entry>
<entry>H</entry>
<entry>88%</entry>
</row>
<row>
<entry>3</entry>
<entry><highlight><superscript>i</superscript></highlight>Bu</entry>
<entry>Me</entry>
<entry>Me</entry>
<entry>&gt;99%&thinsp;&thinsp;</entry>
</row>
<row>
<entry>4</entry>
<entry>Bn</entry>
<entry>H</entry>
<entry>H</entry>
<entry>60%</entry>
</row>
<row>
<entry>5</entry>
<entry>Bn</entry>
<entry>Et</entry>
<entry>H</entry>
<entry>68%</entry>
</row>
<row>
<entry>6</entry>
<entry>CH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight>CO<highlight><subscript>2</subscript></highlight><highlight><superscript>t</superscript></highlight>Bu</entry>
<entry>OTBS</entry>
<entry>H</entry>
<entry>70%</entry>
</row>
<row>
<entry>7</entry>
<entry>CH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>2</subscript></highlight>CO<highlight><subscript>2</subscript></highlight>Et</entry>
<entry>Ph</entry>
<entry>H</entry>
<entry>78%</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 2 </heading>
<paragraph id="P-0117" lvl="0"><number>&lsqb;0117&rsqb;</number> Preparation of C-H Insertion Reaction Precursors from Amino Acids &agr;-Phenylthioacetamide  
<chemistry-cwu id="CHEM-US-00035">
<number>35</number>
<image id="EMI-C00035" he="84.96495" wi="204.26175" file="US20030004337A1-20030102-C00035.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00035" file="US20030004337A1-20030102-C00035.CDX"/>
<chemistry-mol-file id="CHEMMOL-00035" file="US20030004337A1-20030102-C00035.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0118" lvl="0"><number>&lsqb;0118&rsqb;</number> To a solution of amino acid methyl ester VI and imidazole in DMF, is added phenylthioacetic acid followed by diisopropylcarbodiimide at room temperature. The reaction mixture is stirred for 12 hours. After filtration on silica gel pad, the filtrate is poured into water and EtOAc. The organic layer is washed twice with water, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and concentrated to afford a-phenylthioacetamide VII. </paragraph>
<paragraph id="P-0119" lvl="0"><number>&lsqb;0119&rsqb;</number> Alcohol  
<chemistry-cwu id="CHEM-US-00036">
<number>36</number>
<image id="EMI-C00036" he="84.96495" wi="211.9446" file="US20030004337A1-20030102-C00036.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00036" file="US20030004337A1-20030102-C00036.CDX"/>
<chemistry-mol-file id="CHEMMOL-00036" file="US20030004337A1-20030102-C00036.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0120" lvl="0"><number>&lsqb;0120&rsqb;</number> To a solution of &agr;-phenylthioacetamide VII in methanol and THF (v/v&equals;1/1), is added LiCl followed by NaBH<highlight><subscript>4 </subscript></highlight>at 0&deg; C. The reaction mixture is stirred for 1 hour and concentrated under reduced pressure. The residue is diluted with EtOAc, which is washed with 2 N HCl and brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and concentrated to afford VIII. </paragraph>
<paragraph id="P-0121" lvl="0"><number>&lsqb;0121&rsqb;</number> Ketalization  
<chemistry-cwu id="CHEM-US-00037">
<number>37</number>
<image id="EMI-C00037" he="84.00105" wi="211.9446" file="US20030004337A1-20030102-C00037.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00037" file="US20030004337A1-20030102-C00037.CDX"/>
<chemistry-mol-file id="CHEMMOL-00037" file="US20030004337A1-20030102-C00037.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0122" lvl="0"><number>&lsqb;0122&rsqb;</number> To a solution of alcohol VIII in benzene, is added 2,2-dimethoxypropane and a catalytic amount of p-TsOH. The reaction mixture is refluxed for 1 hour, then slowly distilled. The reaction mixture is partitioned between sat&apos;d NaHCO<highlight><subscript>3 </subscript></highlight>solution and ethyl ether. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4 </subscript></highlight>and concentrated to give crude product, which is column chromatographed to give IX. </paragraph>
<paragraph id="P-0123" lvl="0"><number>&lsqb;0123&rsqb;</number> &agr;-Phenylsulfonylacetamide  
<chemistry-cwu id="CHEM-US-00038">
<number>38</number>
<image id="EMI-C00038" he="84.00105" wi="211.7178" file="US20030004337A1-20030102-C00038.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00038" file="US20030004337A1-20030102-C00038.CDX"/>
<chemistry-mol-file id="CHEMMOL-00038" file="US20030004337A1-20030102-C00038.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0124" lvl="0"><number>&lsqb;0124&rsqb;</number> To a solution &agr;-phenylthioacetamide IX in anhydrous dichloromethane, is added m-CPBA at 0&deg; C. The reaction mixture is stirred for 1 hour at room temperature and then treated with 1 N NaOH solution. The organic layer is washed with brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and evaporated. The residue is purified by silica gel column chromatography to give &agr;-phenylsulfonylacetamide X. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 3 </heading>
<paragraph id="P-0125" lvl="0"><number>&lsqb;0125&rsqb;</number> &agr;-Phenylsulfonyl-&agr;-Diazoacetamide </paragraph>
<paragraph id="P-0126" lvl="0"><number>&lsqb;0126&rsqb;</number> a. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>1</bold></highlight>  
<chemistry-cwu id="CHEM-US-00039">
<number>39</number>
<image id="EMI-C00039" he="73.45485" wi="212.9085" file="US20030004337A1-20030102-C00039.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00039" file="US20030004337A1-20030102-C00039.CDX"/>
<chemistry-mol-file id="CHEMMOL-00039" file="US20030004337A1-20030102-C00039.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0127" lvl="0"><number>&lsqb;0127&rsqb;</number> To a solution of the &agr;-phenylsulfonylacetamide X-1 and DBU in anhydrous acetonitrile, is added ABSA (p-N-acetylbenzosulfonylazide). The reaction mixture is stirred for 30 min. at room temperature and is then poured into water. The aqueous layer is extracted twice with EtOAc. The combined organic layer is washed with 10% aqueous NaOH solution and brine, dried over Na<highlight><subscript>2</subscript></highlight>SO<highlight><subscript>4</subscript></highlight>, and then evaporated. The residue is purified by silica gel column chromatography to give &agr;-phenylsulfonyl-&agr;-diazoacetamide XI-<highlight><bold>1</bold></highlight> as yellow oil. </paragraph>
<paragraph id="P-0128" lvl="0"><number>&lsqb;0128&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.31 (d, 3 H, J&equals;5.7 Hz), 1.40 (s, 3 H), 1.60 (s, 3 H), 3.67 (dd, 1 H, J&equals;3.0, 5.5 Hz), 3.98 (m, 1 H), 4.05 (dd, 1 H, J&equals;5.5, 6.3), 7.58 (m, 3 H), 8.0 (d, 2 H, J&equals;7.5 Hz) </paragraph>
<paragraph id="P-0129" lvl="0"><number>&lsqb;0129&rsqb;</number> b. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>2</bold></highlight>  
<chemistry-cwu id="CHEM-US-00040">
<number>40</number>
<image id="EMI-C00040" he="73.1997" wi="212.65335" file="US20030004337A1-20030102-C00040.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00040" file="US20030004337A1-20030102-C00040.CDX"/>
<chemistry-mol-file id="CHEMMOL-00040" file="US20030004337A1-20030102-C00040.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0130" lvl="0"><number>&lsqb;0130&rsqb;</number> Following the procedure of the preparation of XI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XI-<highlight><bold>2</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide X-<highlight><bold>2</bold></highlight>. </paragraph>
<paragraph id="P-0131" lvl="0"><number>&lsqb;0131&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.90 (d, 3 H, J&equals;6.7 Hz), 0.95 (d, 3 H, J&equals;7.0), 1.40 (s, 3 H), 1.64 (s,3H),2.1 (m, 1 H), 3.81 (m, 1 H),3.93(m,2 H), 7.61 (m,3 H), 8.0 (d,J&equals;7.1 Hz) </paragraph>
<paragraph id="P-0132" lvl="0"><number>&lsqb;0132&rsqb;</number> c. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>3</bold></highlight>  
<chemistry-cwu id="CHEM-US-00041">
<number>41</number>
<image id="EMI-C00041" he="90.97515" wi="212.65335" file="US20030004337A1-20030102-C00041.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00041" file="US20030004337A1-20030102-C00041.CDX"/>
<chemistry-mol-file id="CHEMMOL-00041" file="US20030004337A1-20030102-C00041.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0133" lvl="0"><number>&lsqb;0133&rsqb;</number> Following the procedure of the preparation of XI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XI-<highlight><bold>3</bold></highlight> is obtained from a-phenylsulfonylacetamide X-<highlight><bold>3</bold></highlight>. </paragraph>
<paragraph id="P-0134" lvl="0"><number>&lsqb;0134&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.35 (s, 3 H), 1.69 (s, 3 H), 2.82 (dd, 1 H, J&equals;9.3, 13.4), 3.08 (dd, 1 H, J&equals;5.3, 13.4), 3.85 (d, 2 H, J&equals;3.6), 4.3 (m, I H), 7.26 (m, 5 H), 7.57 (m, 3 H), 7.94 (d, 2 H, J&equals;7.2) </paragraph>
<paragraph id="P-0135" lvl="0"><number>&lsqb;0135&rsqb;</number> d. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>4</bold></highlight>  
<chemistry-cwu id="CHEM-US-00042">
<number>42</number>
<image id="EMI-C00042" he="90.72" wi="212.65335" file="US20030004337A1-20030102-C00042.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00042" file="US20030004337A1-20030102-C00042.CDX"/>
<chemistry-mol-file id="CHEMMOL-00042" file="US20030004337A1-20030102-C00042.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0136" lvl="0"><number>&lsqb;0136&rsqb;</number> Following the procedure of the preparation of XI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XI-<highlight><bold>4</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide X-<highlight><bold>4</bold></highlight>. </paragraph>
<paragraph id="P-0137" lvl="0"><number>&lsqb;0137&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.07 (s, 3 H), 0.08 (s, 3 H), 0.87 (s, 9 H), 1.42 (s, 3 H), 1.59 (s, 3 H), 3.65 (m,2 H), 3.98 (m, 3 H), 7.62 (m, 3 H), 8.01 (m, 2 H) </paragraph>
<paragraph id="P-0138" lvl="0"><number>&lsqb;0138&rsqb;</number> e. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>5</bold></highlight>  
<chemistry-cwu id="CHEM-US-00043">
<number>43</number>
<image id="EMI-C00043" he="90.72" wi="212.65335" file="US20030004337A1-20030102-C00043.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00043" file="US20030004337A1-20030102-C00043.CDX"/>
<chemistry-mol-file id="CHEMMOL-00043" file="US20030004337A1-20030102-C00043.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0139" lvl="0"><number>&lsqb;0139&rsqb;</number> Following the procedure of the preparation of XI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XI-<highlight><bold>5</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide X-<highlight><bold>5</bold></highlight>. </paragraph>
<paragraph id="P-0140" lvl="0"><number>&lsqb;0140&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.07 (s, 3H), 0.08 (s, 3 H), 0.87 (s, 9 H), 1.42 (s, 3 H), 1.59 (s, 3 H), 3.65 (m, 2 H), 3.98 (m, 3 H), 8.01 (m, 2 H) </paragraph>
<paragraph id="P-0141" lvl="0"><number>&lsqb;0141&rsqb;</number> f. &agr;-Phenylsulfonyl-&agr;-Diazoacetamide XI-<highlight><bold>6</bold></highlight>  
<chemistry-cwu id="CHEM-US-00044">
<number>44</number>
<image id="EMI-C00044" he="90.72" wi="212.65335" file="US20030004337A1-20030102-C00044.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00044" file="US20030004337A1-20030102-C00044.CDX"/>
<chemistry-mol-file id="CHEMMOL-00044" file="US20030004337A1-20030102-C00044.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0142" lvl="0"><number>&lsqb;0142&rsqb;</number> Following the procedure of the preparation of XI-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XI-<highlight><bold>6</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide X-<highlight><bold>6</bold></highlight>. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 4 </heading>
<paragraph id="P-0143" lvl="0"><number>&lsqb;0143&rsqb;</number> The Synthesis of &ggr;-Lactam via C-H Insertion </paragraph>
<paragraph id="P-0144" lvl="0"><number>&lsqb;0144&rsqb;</number> a. &ggr;-Lactam XII-<highlight><bold>1</bold></highlight>  
<chemistry-cwu id="CHEM-US-00045">
<number>45</number>
<image id="EMI-C00045" he="134.6625" wi="212.19975" file="US20030004337A1-20030102-C00045.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00045" file="US20030004337A1-20030102-C00045.CDX"/>
<chemistry-mol-file id="CHEMMOL-00045" file="US20030004337A1-20030102-C00045.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0145" lvl="0"><number>&lsqb;0145&rsqb;</number> To a solution of the (&agr;-phenylsulfonyl-&agr;-diazoacetamide XI-<highlight><bold>1</bold></highlight> in dry CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>, is added a catalytic amount of Rh<highlight><subscript>2</subscript></highlight>(OAc)<highlight><subscript>4</subscript></highlight>. The mixture was refluxed with stirring for 12 hours under N<highlight><subscript>2</subscript></highlight>, cooled to room temperature, and is then concentrated. The residue is purified by silica gel column chromatography to give &ggr;-lactam XII-<highlight><bold>1</bold></highlight>. </paragraph>
<paragraph id="P-0146" lvl="0"><number>&lsqb;0146&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.39 (s, 3 H), 1.57 (s, 3 H), 2.24 (m, 1 H), 2.92 (m, 1 H), 3.41 (m, 1 H), 4.27 (m, 1 H), 4.32 (m, 1 H), 4.41 (m, 1 H), 7.62 (m, 3 H), 7.91 (m, 2 H) </paragraph>
<paragraph id="P-0147" lvl="0"><number>&lsqb;0147&rsqb;</number> b. &ggr;-Lactam XII-<highlight><bold>2</bold></highlight>  
<chemistry-cwu id="CHEM-US-00046">
<number>46</number>
<image id="EMI-C00046" he="154.1106" wi="212.19975" file="US20030004337A1-20030102-C00046.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00046" file="US20030004337A1-20030102-C00046.CDX"/>
<chemistry-mol-file id="CHEMMOL-00046" file="US20030004337A1-20030102-C00046.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0148" lvl="0"><number>&lsqb;0148&rsqb;</number> Following the procedure of the preparation of XII-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XII-<highlight><bold>2</bold></highlight> is obtained from (&agr;-phenylsulfonylacetamide XI-<highlight><bold>2</bold></highlight>. </paragraph>
<paragraph id="P-0149" lvl="0"><number>&lsqb;0149&rsqb;</number> H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.16 (s, 3 H), 1.37 (s, 3 H), 1.55 (s. 3 H), 1.64 (s, 3 H), 7.60 (m, 3 H), 7.95 (m, 2 H) </paragraph>
<paragraph id="P-0150" lvl="0"><number>&lsqb;0150&rsqb;</number> c. &ggr;-Lactam XII-<highlight><bold>3</bold></highlight>  
<chemistry-cwu id="CHEM-US-00047">
<number>47</number>
<image id="EMI-C00047" he="171.14895" wi="212.19975" file="US20030004337A1-20030102-C00047.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00047" file="US20030004337A1-20030102-C00047.CDX"/>
<chemistry-mol-file id="CHEMMOL-00047" file="US20030004337A1-20030102-C00047.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0151" lvl="0"><number>&lsqb;0151&rsqb;</number> Following the procedure of the preparation of XII-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XII-<highlight><bold>3</bold></highlight> is obtained from a-phenylsulfonylacetamide XI-<highlight><bold>3</bold></highlight>. </paragraph>
<paragraph id="P-0152" lvl="0"><number>&lsqb;0152&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.95 (d, 3 H, J&equals;6.9 Hz), 1.03 (d, 3 H, J&equals;6.7 Hz), 1.45 (s, 3 H), 1.62 (s, 3 H), 2.22 (m, 1 H), 2.79 (m, 1 H), 3.59 (dd, 1 H, J&equals;8.0, 9.3 Hz), 3.89 (ddd, 1 H, J&equals;5.5, 5.6, 9.3 Hz), 4.07 (dd, 1 H, J&equals;5.5, 8.0Hz), 4.16 (d, H, J&equals;8.2 Hz), 7.68 (m, 3 H), 8.0 (d, 2 H, J&equals;7.3 Hz) </paragraph>
<paragraph id="P-0153" lvl="0"><number>&lsqb;0153&rsqb;</number> d. &ggr;-Lactam XII-<highlight><bold>4</bold></highlight>  
<chemistry-cwu id="CHEM-US-00048">
<number>48</number>
<image id="EMI-C00048" he="153.3735" wi="153.1467" file="US20030004337A1-20030102-C00048.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00048" file="US20030004337A1-20030102-C00048.CDX"/>
<chemistry-mol-file id="CHEMMOL-00048" file="US20030004337A1-20030102-C00048.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0154" lvl="0"><number>&lsqb;0154&rsqb;</number> Following the procedure of the preparation of XII-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XII-<highlight><bold>4</bold></highlight> is obtained from a-phenylsulfonylacetamide XI-<highlight><bold>4</bold></highlight>. </paragraph>
<paragraph id="P-0155" lvl="0"><number>&lsqb;0155&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.45 (s, 3 H), 1.65 (s, 3 H), 3.68 (dd, 1 H, J&equals;7.9, 8.0 Hz), 3.88 (dd, 1 H, J&equals;6.2, 9.1 Hz), 4.1 (m, 2 H), 4.5 (d, 1 H, J&equals;9.1 Hz), 7.3 (m, 5 H, Ph), 7.50 7.6 (m, 3 H), 7.91 (d, 2 H, J&equals;7.2 Hz) </paragraph>
<paragraph id="P-0156" lvl="0"><number>&lsqb;0156&rsqb;</number> e. &ggr;-Lactam XII-<highlight><bold>5</bold></highlight>  
<chemistry-cwu id="CHEM-US-00049">
<number>49</number>
<image id="EMI-C00049" he="150.0282" wi="211.9446" file="US20030004337A1-20030102-C00049.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00049" file="US20030004337A1-20030102-C00049.CDX"/>
<chemistry-mol-file id="CHEMMOL-00049" file="US20030004337A1-20030102-C00049.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0157" lvl="0"><number>&lsqb;0157&rsqb;</number> Following the procedure of the preparation of XII-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XII-<highlight><bold>5</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide XI-<highlight><bold>5</bold></highlight>. </paragraph>
<paragraph id="P-0158" lvl="0"><number>&lsqb;0158&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (360 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;0.15 (s, 3 H), 0.24 (s, 3 H), 0.93 (s, 9 H), 1.47 (s, 3 H), 1.59 (s, 3 H), 3.59 (dd, 1 H, J&equals;10.3, 9.4 Hz), 3.97 (m, 1 H), 4.16 (dd, 1 H, J&equals;8.2, 6.8 Hz), 4.26 (d, 1 H, J&equals;6.8 Hz), 4.83 (dd, 1 H, J&equals;6.8, 4.9 Hz), 7.62 (m, 3 H), 7.9 (d, 2 H, J&equals;7.2 Hz) </paragraph>
<paragraph id="P-0159" lvl="0"><number>&lsqb;0159&rsqb;</number> f. &ggr;-Lactam XII-<highlight><bold>6</bold></highlight>  
<chemistry-cwu id="CHEM-US-00050">
<number>50</number>
<image id="EMI-C00050" he="179.31375" wi="212.65335" file="US20030004337A1-20030102-C00050.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00050" file="US20030004337A1-20030102-C00050.CDX"/>
<chemistry-mol-file id="CHEMMOL-00050" file="US20030004337A1-20030102-C00050.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0160" lvl="0"><number>&lsqb;0160&rsqb;</number> Following the procedure of the preparation of XII-<highlight><bold>1</bold></highlight>, &agr;-phenylsulfonylacetamide XII-<highlight><bold>6</bold></highlight> is obtained from &agr;-phenylsulfonylacetamide XI-<highlight><bold>6</bold></highlight>. </paragraph>
<paragraph id="P-0161" lvl="0"><number>&lsqb;0161&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR (250 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;1.43 (s, 3 H), 1.52 (s, 3 H), 2.71 (dd, 1 H, J&equals;15.5, 10.5 Hz), 3.13 (m, 1 H), 3.27 (dd, 1 H, J&equals;15.5 3.3 Hz), 3.61 (t, 1 H, J&equals;8.9 Hz), 3.76 (s, 3 H), 3.85 (m, 1 H), 4.25 (m, 2 H), 7.55 (m, 5 H) </paragraph>
<paragraph id="P-0162" lvl="0"><number>&lsqb;0162&rsqb;</number> The results for this Example are collected in Table 3:  
<table-cwu id="TABLE-US-00003">
<number>3</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE 3</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Stereoselective &ggr;-Lactam Synthesis from Amino Acid</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="140PT" align="left"/>
<colspec colname="2" colwidth="77PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry>
<chemistry-cwu id="CHEM-US-00051">
<number>51</number>
<image id="EMI-C00051" he="57.834" wi="135.14445" file="US20030004337A1-20030102-C00051.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00051" file="US20030004337A1-20030102-C00051.CDX"/>
<chemistry-mol-file id="CHEMMOL-00051" file="US20030004337A1-20030102-C00051.MOL"/>
</chemistry-cwu>
</entry>
<entry>
<chemistry-cwu id="CHEM-US-00052">
<number>52</number>
<image id="EMI-C00052" he="53.5248" wi="76.57335" file="US20030004337A1-20030102-C00052.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00052" file="US20030004337A1-20030102-C00052.CDX"/>
<chemistry-mol-file id="CHEMMOL-00052" file="US20030004337A1-20030102-C00052.MOL"/>
</chemistry-cwu>
</entry>
</row>
<row>
<entry> </entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="63PT" align="center"/>
<colspec colname="2" colwidth="63PT" align="left"/>
<colspec colname="3" colwidth="21PT" align="left"/>
<colspec colname="4" colwidth="70PT" align="center"/>
<tbody valign="top">
<row>
<entry>entry</entry>
<entry>R<highlight><superscript>4</superscript></highlight></entry>
<entry>R<highlight><superscript>5</superscript></highlight></entry>
<entry>Yield</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry>1</entry>
<entry>Me</entry>
<entry>Me</entry>
<entry>68%</entry>
</row>
<row>
<entry>2</entry>
<entry>Me</entry>
<entry>H</entry>
<entry>67%</entry>
</row>
<row>
<entry>3</entry>
<entry>CH(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight></entry>
<entry>H</entry>
<entry>72%</entry>
</row>
<row>
<entry>4</entry>
<entry>Ph</entry>
<entry>H</entry>
<entry>91%</entry>
</row>
<row>
<entry>5</entry>
<entry>OTBS</entry>
<entry>H</entry>
<entry>97%</entry>
</row>
<row>
<entry>6</entry>
<entry>CH<highlight><subscript>2</subscript></highlight>CO<highlight><subscript>2</subscript></highlight>Me</entry>
<entry>H</entry>
<entry>48%</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 8 </heading>
<paragraph id="P-0163" lvl="0"><number>&lsqb;0163&rsqb;</number> Total Synthesis of Lactacystin </paragraph>
<paragraph id="P-0164" lvl="0"><number>&lsqb;0164&rsqb;</number> Central to the synthesis of lactacystin and its analoges is the stereoselectivity of the key step, namely intramolecular C-H insertion, which is further demonstrated herein. Hence, a &agr;-diazoamide containing serine moiety is prepared in an expeditious fashion as delineated below. As discussed earlier, the reaction is efficient and the observed stereoselectivity is good. Because the cyclization product is only a few simple steps from the natural product, the total synthesis of lactacystin is completed, and the newly formed stereochemistry is confirmed through spectral comparison with the natural product.  
<chemistry-cwu id="CHEM-US-00053">
<number>53</number>
<image id="EMI-C00053" he="437.58225" wi="212.42655" file="US20030004337A1-20030102-C00053.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00053" file="US20030004337A1-20030102-C00053.CDX"/>
<chemistry-mol-file id="CHEMMOL-00053" file="US20030004337A1-20030102-C00053.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0165" lvl="0"><number>&lsqb;0165&rsqb;</number> Starting with (L)-serine, &bgr;-phenylsulfonylamide <highlight><bold>34</bold></highlight> is made almost quantitatively by esterification, silylation, and amidation. Removal of the silyl protecting group gives the primary alcohol, which is assembled with the amide as an acetonide. Ester <highlight><bold>35</bold></highlight> is subjected to selective reduction and the resulting alcohol is masked as TBS ether. Sequential oxidation and diazo transfer provide the cyclization precursor in high yield. Intramolecular C-H insertion yields the pyrrolidinone ring and the ensuing methylation generates a single diastereomer <highlight><bold>37</bold></highlight>. As expected, the methyl group is introduced away from the bulky neighboring group. With the exception of the silylation and acetonide formation, each step gives high yields (&gt;90%) without side product formation, and bicyclic lactam <highlight><bold>37</bold></highlight> is obtained on a multigram scale. </paragraph>
<paragraph id="P-0166" lvl="0"><number>&lsqb;0166&rsqb;</number> Expeditious Synthesis of Lactacystin </paragraph>
<paragraph id="P-0167" lvl="0"><number>&lsqb;0167&rsqb;</number> Methylated lactam <highlight><bold>37</bold></highlight> has the unnatural stereochemistry at the silyl ether bearing carbon, and the synthesis of the unnatural enantiomer is performed, for unambiguous elucidation of relative stereochemistry. After RuO<highlight><subscript>4 </subscript></highlight>oxidation, an aldol condensation forms the C-C bond at the ring junction, and the stereochemistry is controlled by the pre-existing ether group. Aldol stereochemistry also favors the desired configuration. Desulfonylation and removal of the acetonide secures the dihydroxyacid <highlight><bold>39</bold></highlight>, which is a common intermediate for the synthesis of lactacystin. As this compound is two steps away from the target, the overall synthesis in the unnatural form requires 17 steps, and the yield of each step is satisfactory. One notable feature in this synthesis is to utilize the stereochemistry of an amino acid for stereochemical sense at the adjacent ether center, which in turn controls the stereochemistry at the other two carbons. Stereocontrol is highly feasible due to the rigidity of the bicyclic lactam, which is a crucial feature in asymmetric synthesis.  
<chemistry-cwu id="CHEM-US-00054">
<number>54</number>
<image id="EMI-C00054" he="321.1488" wi="397.72215" file="US20030004337A1-20030102-C00054.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00054" file="US20030004337A1-20030102-C00054.CDX"/>
<chemistry-mol-file id="CHEMMOL-00054" file="US20030004337A1-20030102-C00054.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0168" lvl="0"><number>&lsqb;0168&rsqb;</number> Another alternative route is available as depicted above, which starts from the benzyl ether <highlight><bold>40</bold></highlight>. Acid catalyzed hydrolysis followed by Jones oxidation affords the corresponding carboxylic acid, which is methylated to furnish ester <highlight><bold>41</bold></highlight>. Using similar sequences, this monocyclic intermediate is transformed to the known compound for the natural product synthesis. </paragraph>
<paragraph id="P-0169" lvl="0"><number>&lsqb;0169&rsqb;</number> Subsequently, synthesis of the natural form is initiated, as described herein. The aforementioned synthesis adopts method A, while the present route exploits route B. Synthesis begins with the protection of each serine functionality to provide &bgr;-sulfonylamide <highlight><bold>42</bold></highlight>, which are converted to diazo compound <highlight><bold>43</bold></highlight> following the previously schemes. Cyclization, via a C-H insertion reaction, produces bicyclic lactam <highlight><bold>44</bold></highlight>. Methylation and aldol condensation secure the necessary functional groups and deprotection of masking groups secures the natural stereochemistry. To reach this intermediate requires eleven steps.  
<chemistry-cwu id="CHEM-US-00055">
<number>55</number>
<image id="EMI-C00055" he="459.41175" wi="212.65335" file="US20030004337A1-20030102-C00055.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00055" file="US20030004337A1-20030102-C00055.CDX"/>
<chemistry-mol-file id="CHEMMOL-00055" file="US20030004337A1-20030102-C00055.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0170" lvl="0"><number>&lsqb;0170&rsqb;</number> Synthesis of acyclic substrates for &ggr;-lactam synthesis (method C) in pursuit of clasto-lactacystin &bgr;-lactone (<highlight><bold>2</bold></highlight>), is summarized herein. The cesium base promoted alkylation of serine gives rise to predominant formation of N-benzylserine benzyl ester without affecting hydroxyl, and this product forms the P-lactone under various basic conditions to give lactone <highlight><bold>48</bold></highlight> after the introduction of &bgr;-phenylsulfonylacetic acid. Since the &lsqb;3.2.0.&rsqb;bicycloheptane system is being prepared, the 1,2-asymmetric induction are exclusively favored to cis fused ring <highlight><bold>50</bold></highlight>. </paragraph>
<paragraph id="P-0171" lvl="0"><number>&lsqb;0171&rsqb;</number> Methylation and aldol condensation is smooth and stereoselective, and removal of sulfonyl and benzyl groups delivers lactone <highlight><bold>2</bold></highlight>. The synthesis consists of eight steps. </paragraph>
<paragraph id="P-0172" lvl="0"><number>&lsqb;0172&rsqb;</number> In addition, the targeted natural products can also be synthesized by method C (acyclic substrates).  
<chemistry-cwu id="CHEM-US-00056">
<number>56</number>
<image id="EMI-C00056" he="471.177" wi="212.42655" file="US20030004337A1-20030102-C00056.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00056" file="US20030004337A1-20030102-C00056.CDX"/>
<chemistry-mol-file id="CHEMMOL-00056" file="US20030004337A1-20030102-C00056.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0173" lvl="0"><number>&lsqb;0173&rsqb;</number> In the disclosed syntheses, the feasibility of these three methods is demonstrated in &ggr;-lactam synthesis via an intramolecular rhodium(II) catalyzed C-H insertion of &agr;-diazo-&bgr;-phenylsulfonylacetamides containing amino acid derivatives. These syntheses also illustrate features in asymmetric synthesis, which are 1,2- and 1,3-asymmetric induction during C-C bond formations. </paragraph>
<paragraph id="P-0174" lvl="0"><number>&lsqb;0174&rsqb;</number> In the above lactacystin syntheses, three different methods of C-H insertion are utilized. The following section further illustrates use of the &ggr;-lactam synthons in several natural product syntheses via all four aforementioned methods. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 9 </heading>
<paragraph id="P-0175" lvl="0"><number>&lsqb;0175&rsqb;</number> Synthesis of Pramanicin by Method A </paragraph>
<paragraph id="P-0176" lvl="0"><number>&lsqb;0176&rsqb;</number> Pramanicin is isolated from a fungus, Stagonospora, and comprises a highly functionalized &ggr;-lactam headgroup (<cross-reference target="DRAWINGS">FIG. 1</cross-reference>). This compound also exhibits activity against the acapsular form of <highlight><italic>Cryptococcus neoformans. </italic></highlight> 
<chemistry-cwu id="CHEM-US-00057">
<number>57</number>
<image id="EMI-C00057" he="210.9807" wi="212.42655" file="US20030004337A1-20030102-C00057.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00057" file="US20030004337A1-20030102-C00057.CDX"/>
<chemistry-mol-file id="CHEMMOL-00057" file="US20030004337A1-20030102-C00057.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0177" lvl="0"><number>&lsqb;0177&rsqb;</number> Bicyclic &ggr;-lactam <highlight><bold>54</bold></highlight>, which is derived from (L)-serine via method A. The acid chloride <highlight><bold>53</bold></highlight> or corresponding aldehyde is introduced to the &agr;-center of &ggr;-lactam <highlight><bold>54</bold></highlight>, and the resulting coupling product is subjected to removal of protecting groups. Hydroxylation at the &agr;-center is carried out by using one of several conventional methods. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 10 </heading>
<paragraph id="P-0178" lvl="0"><number>&lsqb;0178&rsqb;</number> Synthesis of Kainic Acid by Method B </paragraph>
<paragraph id="P-0179" lvl="0"><number>&lsqb;0179&rsqb;</number> Kainic acid is a neuronal excitant and has facilitated research on Alzeheimer&apos;s disease and epilepsy. In this example, a 9 step synthesis is disclosed as shown below. This synthesis is performed using the strategy similar to the previously discussed method B. </paragraph>
<paragraph id="P-0180" lvl="0"><number>&lsqb;0180&rsqb;</number> Starting with glutamic acid, selective protection of &agr;-amino acid moieties followed by esterification of the residual &ggr;-acid ensures the formation of oxaolidinone <highlight><bold>56</bold></highlight>, which in turn is converted to diazoamide <highlight><bold>57</bold></highlight> through sequential amide formation and diazo transfer. Applying the C-H insertion protocol (method B), bicyclic lactam <highlight><bold>58</bold></highlight> is prepared in a stereoselective manner.  
<chemistry-cwu id="CHEM-US-00058">
<number>58</number>
<image id="EMI-C00058" he="527.11155" wi="212.65335" file="US20030004337A1-20030102-C00058.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00058" file="US20030004337A1-20030102-C00058.CDX"/>
<chemistry-mol-file id="CHEMMOL-00058" file="US20030004337A1-20030102-C00058.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0181" lvl="0"><number>&lsqb;0181&rsqb;</number> Selective methylenation gives rise to the formation of olefin <highlight><bold>59</bold></highlight>. The amide is reduced selectively using the reported two step sequence (Mateo, A. I. &amp; Rubio, A. &ldquo;Stereocontrolled Synthesis of 4-Substituted Kanaic Acid&rdquo; 1998, J. Org. Chem. 63:1995), then the subsequent hydrolysis secures the natural product <highlight><bold>60</bold></highlight>. </paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 11 </heading>
<paragraph id="P-0182" lvl="0"><number>&lsqb;0182&rsqb;</number> Synthesis of Statine and AHPPA by Method C </paragraph>
<paragraph id="P-0183" lvl="0"><number>&lsqb;0183&rsqb;</number> Statine (<highlight><bold>61</bold></highlight>) is a nonprotein organic compound, which constitutes a key component of the naturally occurring peptidic aspartate protease inhibitor pepstatin. The potential inhibitory activity of pepstatin and its structural analogs, especially AHPPA, towards the aspartate proteases prompted synthetic efforts. </paragraph>
<paragraph id="P-0184" lvl="0"><number>&lsqb;0184&rsqb;</number> These simple chiral compounds can be derived from the &ggr;-lactams prepared via method C (acyclic substrates). As retrosynthetically illustrated below, statine and AHPPA are synthesized from &ggr;-lactams, starting from leucine and phenylalanine, respectively. Appropriate deprotection of masking groups delivers lactams <highlight><bold>62</bold></highlight> and <highlight><bold>65</bold></highlight>, which are transformed to the natural products by hydrolysis. Although there are more synthetic steps in these syntheses than simply an efficient asymmetric aminohydroxylation, this route secures optical purity, and the intermediates allow a variety of highly functionalized analogs.  
<chemistry-cwu id="CHEM-US-00059">
<number>59</number>
<image id="EMI-C00059" he="610.8858" wi="215.8002" file="US20030004337A1-20030102-C00059.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00059" file="US20030004337A1-20030102-C00059.CDX"/>
<chemistry-mol-file id="CHEMMOL-00059" file="US20030004337A1-20030102-C00059.MOL"/>
</chemistry-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 12 </heading>
<paragraph id="P-0185" lvl="0"><number>&lsqb;0185&rsqb;</number> Synthesis of Rolipram and Epolactaene by Method D </paragraph>
<paragraph id="P-0186" lvl="0"><number>&lsqb;0186&rsqb;</number> This example illustrates the synthesis of two pharmaceutically important compounds, rolipram and epolactaene, utilizing method D. Rolipram is an antidepressant and a potent inhibitor of phosphodiesterase type IV. </paragraph>
<paragraph id="P-0187" lvl="0"><number>&lsqb;0187&rsqb;</number> As delineated below, the synthesis of rolipram requires 10 linear steps via the chiral auxiliary <highlight><bold>26</bold></highlight>. Aldehyde <highlight><bold>67</bold></highlight> is derived from isovanillin, which is then subjected to the coupling with <highlight><bold>26</bold></highlight> to acquire <highlight><bold>68</bold></highlight>. The syn diastereomer is obtained exclusively. Oxidation followed by diazo transfer affords the C-H insertion precursor <highlight><bold>69</bold></highlight>. Cyclization leads to the stereoselective synthesis of the bicyclic lactam <highlight><bold>70</bold></highlight>, which is converted to rolipram <highlight><bold>71</bold></highlight> via sequential defunctionalizations.  
<chemistry-cwu id="CHEM-US-00060">
<number>60</number>
<image id="EMI-C00060" he="677.36655" wi="212.42655" file="US20030004337A1-20030102-C00060.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00060" file="US20030004337A1-20030102-C00060.CDX"/>
<chemistry-mol-file id="CHEMMOL-00060" file="US20030004337A1-20030102-C00060.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0188" lvl="0"><number>&lsqb;0188&rsqb;</number> Likewise, epolactaene <highlight><bold>72</bold></highlight> is prepared using the known synthetic pathways as illustrated retrosynthetically in Scheme T. Synthetic intermediate <highlight><bold>74</bold></highlight> is a good coupling partner with the known side chain <highlight><bold>73</bold></highlight>. Synthesis of cyclization product <highlight><bold>74</bold></highlight> utilizes method D.  
<chemistry-cwu id="CHEM-US-00061">
<number>61</number>
<image id="EMI-C00061" he="397.2402" wi="212.19975" file="US20030004337A1-20030102-C00061.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00061" file="US20030004337A1-20030102-C00061.CDX"/>
<chemistry-mol-file id="CHEMMOL-00061" file="US20030004337A1-20030102-C00061.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0189" lvl="0"><number>&lsqb;0189&rsqb;</number> After ketone <highlight><bold>75</bold></highlight> and chiral template <highlight><bold>26</bold></highlight> are coupled, oxidation and diazo transfer yields <highlight><bold>76</bold></highlight>. Intramolecular C-H insertion smoothly yields the bicyclic compound <highlight><bold>74</bold></highlight>, which is conjugated with <highlight><bold>73</bold></highlight>. </paragraph>
<paragraph id="P-0190" lvl="0"><number>&lsqb;0190&rsqb;</number> Certain patents and printed publications are referred to herein. All such patents and printed publications are herein incorporated by reference in their respective entireties. </paragraph>
<paragraph id="P-0191" lvl="0"><number>&lsqb;0191&rsqb;</number> The many features and advantages of the invention are apparent from the detailed specification, and thus, it is intended by the appended claims to cover all such features and advantages of the invention which fall within the true spirit and scope of the invention. Further, since numerous modifications and variations will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation illustrated and described, and accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the invention. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<heading lvl="1">What is claimed is: </heading>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. A method of synthesizing a lactam, said method comprising: 
<claim-text>providing an &agr;-diazoacetamide of structure (I), </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00062">
<number>62</number>
<image id="EMI-C00062" he="79.69185" wi="162.729" file="US20030004337A1-20030102-C00062.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00062" file="US20030004337A1-20030102-C00062.CDX"/>
<chemistry-mol-file id="CHEMMOL-00062" file="US20030004337A1-20030102-C00062.MOL"/>
</chemistry-cwu>
</claim-text>
<claim-text>&emsp;in which: </claim-text>
<claim-text>R<highlight><subscript>1</subscript></highlight>, R<highlight><subscript>4</subscript></highlight>, R<highlight><subscript>5</subscript></highlight>, and R<highlight><subscript>6 </subscript></highlight>are independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl; and </claim-text>
<claim-text>R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, &mdash;CH(OH)&mdash;CH(CH<highlight><subscript>3</subscript></highlight>)&mdash;C(O)&mdash;, &mdash;C(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;, &mdash;(CH<highlight><subscript>2</subscript></highlight>)<highlight><subscript>n</subscript></highlight>&mdash;O&mdash;C(O)&mdash;, or &mdash;C(X)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;, where n&equals;0-10, and X is (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl or (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, or R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>are independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl; and </claim-text>
<claim-text>reacting said &agr;-diazoacetamide under conditions promoting intramolecular C-H insertion, whereby said lactam is synthesized. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, in which R<highlight><subscript>1 </subscript></highlight>is phenyl. </claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, in which R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise &mdash;C(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;. </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, in which R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise &mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;C(O)&mdash;. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, in which R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise &mdash;C(Y)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;, where Y is (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. A lactam synthesized by the method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. A library of lactams synthesized by the method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. A method of synthesizing a pyrrolidinone precursor, said method comprising: 
<claim-text>providing an &agr;-diazoacetamide of structure (I), </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00063">
<number>63</number>
<image id="EMI-C00063" he="79.69185" wi="162.729" file="US20030004337A1-20030102-C00063.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00063" file="US20030004337A1-20030102-C00063.CDX"/>
<chemistry-mol-file id="CHEMMOL-00063" file="US20030004337A1-20030102-C00063.MOL"/>
</chemistry-cwu>
</claim-text>
<claim-text>&emsp;in which: </claim-text>
<claim-text>R<highlight><subscript>1</subscript></highlight>, R<highlight><subscript>4</subscript></highlight>, R<highlight><subscript>5</subscript></highlight>, and R<highlight><subscript>6 </subscript></highlight>are independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C-<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl; and </claim-text>
<claim-text>R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>together comprise (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, &mdash;CH(OH)&mdash;CH(CH<highlight><subscript>3</subscript></highlight>)&mdash;C(O)&mdash;, &mdash;C(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;, &mdash;(CH<highlight><subscript>2</subscript></highlight>)<highlight><subscript>n</subscript></highlight>&mdash;O&mdash;C(O)&mdash;, or &mdash;C(X)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;O&mdash;, where n&equals;0-10, and X is (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl or (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, or R<highlight><subscript>2 </subscript></highlight>and R<highlight><subscript>3 </subscript></highlight>are independently H, halo, N<highlight><subscript>3</subscript></highlight>, CN, NC, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl, OR, SR, N(R)<highlight><subscript>2</subscript></highlight>, NH(R), CO<highlight><subscript>2</subscript></highlight>R, C(O)R, P(O)(OR)<highlight><subscript>2</subscript></highlight>, COR, CF<highlight><subscript>3</subscript></highlight>, S(O)R, or SO<highlight><subscript>2</subscript></highlight>R, wherein each R is independently H, (C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkyl, (C<highlight><subscript>6</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>)aryl, (C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkyl, (C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>22</subscript></highlight>)alkenyl, (C<highlight><subscript>5</subscript></highlight>-C<highlight><subscript>8</subscript></highlight>)cycloalkenyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkyl, (C<highlight><subscript>7</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkylaryl, (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)aralkenyl, or (C<highlight><subscript>9</subscript></highlight>-C<highlight><subscript>32</subscript></highlight>)alkenylaryl; and </claim-text>
<claim-text>reacting said &agr;-diazoacetamide under conditions promoting intramolecular C-H insertion, whereby said is pyrrolidinone precursor is synthesized. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00008">claim 8</dependent-claim-reference>, in which said pyrrolidinone precursor is lactacystin, pramanicin, kainic acid, statine, AHPPA, rolipram, or a salt or enantiomer thereof. </claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> in which said conditions promoting intramolecular C-H insertion comprise the addition of an effective amount of a rhodium salt. </claim-text>
</claim>
<claim id="CLM-00011">
<claim-text><highlight><bold>11</bold></highlight>. The method of <dependent-claim-reference depends_on="CLM-00011">claim 10</dependent-claim-reference> in which said rhodium salt is Rh<highlight><subscript>2</subscript></highlight>(OAc)<highlight><subscript>4</subscript></highlight>.</claim-text>
</claim>
</subdoc-claims>
<subdoc-drawings id="DRAWINGS">
<heading lvl="0" align="CENTER">Drawings</heading>
<representative-figure>NONE</representative-figure>
<figure id="figure-D00001">
<image id="EMI-D00001" file="US20030004337A1-20030102-D00001.TIF" imf="TIFF" ti="DR"/>
</figure>
</subdoc-drawings>
</patent-application-publication>
